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 Summary 
It is now well established that within a tumor mass there is a hierarchical organization, 
stemming from a cell subpopulation retaining the highest tumorigenic potential, 
referred as cancer stem cells (CSCs), responsible for tumor initiation and progression.  
 
Although recent advances in stem cell biology led to the acquisition of new view of 
thyroid carcinoma as a stem cell disease, the cellular origin of thyroid CSCs remains 
unknown. In Chapter 1 it is critically discussed the potential role of thyroid stem 
cells (TSCs) in light of the available information on the oncogenic role of genetic 
alterations underlying the thyroid carcinogenesis. Understanding the key events that 
regulate thyroid transformation may be fundamental for clinical intervention in terms 
of prevention, diagnosis and therapy.  
 
Although stem cells (SCs), with their unique self-renewal potential, are considered the 
favored candidates for sequential accumulation of genetic alterations in tumor 
transformation, any cell with proliferative capacity, within the hierarchy in a normal 
tissues, could be considered a cell of origin able to initiate a tumor. In the second 
chapter of this thesis (Chapter 2), we describe how the in vitro differentiation of 
human embryonic stem cells (hESCs) represents a reliable experimental approach to 
obtain an unlimited source of derived thyroid cells at different stages of 
differentiation. Understanding the cellular hierarchy of normal thyroid tissue could 
allow the identification of cells-of-origin and tumor-related driven mutations 
underlying the thyroid carcinogenesis. 
 
 
It is widely assumed that estrogens play an important role in the initiation and 
progression of different malignancies through their interaction with SC compartment. 
Based on this scenario, direct effects of estrogens in growth and function of normal 
and malignant thyroid cells are closely described in Chapter 3.  
 
A growing body of evidence suggested that CSCs could be considered a source of 
primary mediators of chemo-radiation resistance leading to failure in cancer therapy. 
A better understanding of molecular mechanisms underlying CSCs resistance may 
1
 improve the efficacy of current cancer therapies. In the fourth chapter of this thesis 
(Chapter 4), we suggest that targeting CSCs metabolism is a potential alternative 
strategy to cancer therapy. 
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REVIEW
Normal vs cancer thyroid stem cells: the road to
transformation
M Zane1,2,4, E Scavo1,4, V Catalano1, M Bonanno1, M Todaro1, R De Maria3 and G Stassi1
Recent investigations in thyroid carcinogenesis have led to the isolation and characterisation of a subpopulation of stem-like cells,
responsible for tumour initiation, progression and metastasis. Nevertheless, the cellular origin of thyroid cancer stem cells (SCs)
remains unknown and it is still necessary to deﬁne the process and the target population that sustain malignant transformation of
tissue-resident SCs or the reprogramming of a more differentiated cell. Here, we will critically discuss new insights into thyroid SCs
as a potential source of cancer formation in light of the available information on the oncogenic role of genetic modiﬁcations that
occur during thyroid cancer development. Understanding the ﬁne mechanisms that regulate tumour transformation may provide
new ground for clinical intervention in terms of prevention, diagnosis and therapy.
Oncogene advance online publication, 11 May 2015; doi:10.1038/onc.2015.138
INTRODUCTION
Thyroid cancer (TC) accounts for 96% of endocrine malignancies
with 62 980 new cases expected to be diagnosed in the US in
2014, where it represents the second most common cancer
among adolescents ages 15–19 (www.cancer.org). Despite of a
global increase in incidence over the past three decades, the
mortality rate remains low. This is a consequence of a favourable
prognosis for the more frequent well-differentiated forms,
subdivided into papillary (PTC) and follicular TC (FTC).1 By
retaining the differentiated features of normal thyrocytes, includ-
ing the ability to concentrate iodine, in most cases these tumours
can be treated successfully by surgical resection, followed by
radioactive-iodine administration.2 In contrast, the rare undiffer-
entiated anaplastic TCs (ATCs), have a very-poor prognosis
because of their invasiveness and metastatic behaviour
(Figure 1) as well as their insensitivity to radioactive-iodine
treatment for lack of an iodine symporter.3
Alterations in key signalling pathways are proposed for distinct
forms of thyroid transformation. Gain-of-function mutations in the
thyrotropin receptor (TSH-R) or Gsα encoding genes, result in
increased cAMP accumulation and TSH-independent proliferation,
which in turn account for hyperfunctional adenomas, benign
lesions without propensity towards malignant progression.
Constitutive activation of the MAPK pathway seems to be the
hallmark of different forms of TC.2 Genomic alterations of the
proto-oncogene tyrosine-protein kinase receptor Ret, the neuro-
trophic tyrosine kinase receptor, as well as the intracellular signal
transducer Ras and the serine/threonine-protein kinase B-Raf,
have clearly been implicated in the pathogenesis of PTCs.4
Similarly, the chromosomal translocation t(2;3)(q13;p25), which
fuses the transcription factor paired box protein Pax-8 (Pax-8) and
peroxisome proliferator-activated receptor gamma (PPAR-γ)
encoding genes, has been identiﬁed in signiﬁcant proportions in
FTCs.5 In addition to RAS mutations, another common event of
these tumours is the PI3K pathway aberrant activation through
mutation of the catalytic subunit p110 (PI3KCA) and loss of PTEN
(Figure 2).6
The multistep carcinogenesis model suggests that ATCs arise by
way of a dedifferentiation process from pre-existing FTC or PTC
(Figure 3).7 The additional genetic events involved in the
progression towards tumour dedifferentiation are (i) the inactivat-
ing point mutation in the TP53 gene8–10 and (ii) the activating
mutation in the β-catenin encoding gene CTNNB1.11,12 Evidence in
favour of this multistep carcinogenesis model includes, the
presence of well-differentiated TC within ATC specimens and the
coexistence of BRAF gene and TP53 gene mutations in both
undifferentiated and differentiated carcinomas.13,14 However, this
model is not in accordance with the rare occurrence of RET/PTC
and PAX8/PPARG rearrangements in ATC15 and the low turnover
rate of thyroid follicular cells (about ﬁve renewals per lifetime) that
reduces the possibility of accumulating the mutations needed for
transformation.8,16–18
The existence of several differentiation degrees has led to the
assumption that TC cells are derived from remnants of fetal
thyroid cells, such as stem cells (SCs) or precursors, rather than
mature follicular cells.9,19,20 According to this fetal cell carcinogen-
esis model supported by gene expression proﬁling data, ATC
arises from fetal thyroid SCs, marked by the onco-fetal ﬁbronectin
expression and lack of differentiation markers. Thyroblasts are
hypothesised to be at the origin of PTC and are characterised by
the concomitant expression of onco-fetal ﬁbronectin, and the
more differentiated marker thyroglobulin (Tg). Remnants of pro-
thyrocytes, which represent a more differentiated cell type
not expressing onco-fetal ﬁbronectin, would result in FTC
(Figure 3).7,20 Genomic alterations, including mutations in TP53
and BRAF genes, as well as RET/PTC and PAX8/PPARG rearrange-
ments, have an oncogenic role by conferring proliferative
advantages and preventing fetal thyroid cells from differentiating.
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This model is sustained by several lines of evidence. Exposure to
the radioactive-iodine released after the Chernobyl nuclear
accident resulted in a higher incidence of PTCs among infants
and young children rather than adults.21 Furthermore, thyroid-
targeted transgenic RET/PTC1 mice developed PTC and hypothyr-
oidism following the inhibition of thyroid cell differentiation.7,22
The third model concerns the so-called cancer SCs (CSCs), a
minute population at the apex of a hierarchical pyramid including
increasing numbers of progenitors and more differentiated cells.
This CSC model is based on the assumption that only a small
subset of cells possesses the ability to initiate and spread the
tumour. These cells can arise after genetic and epigenetic
alterations occurring either in normal SCs or in progenitor/
precursor cells that could acquire self-renewal potential in a sort of
reprogramming process.7,23
Here, we describe the potential role of SCs in thyroid
pathogenesis in detail and we address the hypothesis of their
possible involvement in metastasis development.
NORMAL THYROID STEM CELLS
SCs are undifferentiated cells characterised by the extraordinary
ability to self-renew and give rise to many types of specialised
cells.24 They mostly divide asymmetrically to generate two
different daughter cells, one identical to the mother and one
more differentiated that will eventually give rise to specialised
cells. This mechanism allows to maintain control over the SC pool
preserving tissue homeostasis.25 The protective microenvironment
created by the SC niche provides the necessary stimulatory and
inhibitory signals for the maintenance of the stemness state.26
Under particular circumstances requiring the expansion of the SC
pool, SCs undergo symmetric division, producing two identical
daughter cells able to self-renew and generate a differentiated
progeny.27
SCs are usually classiﬁed into three major groups according to
their development potential: embryonic SCs (ESCs), adult SCs
(ASCs) and fetal SCs (FSCs).24 The fate of SCs is inﬂuenced by
speciﬁc signals coming from the microenvironment niche and can
be manipulated in vitro to form differentiated lineages. ESCs
represent a potential source of derived thyroid cells that have a
superior predilection to mutate and hence initiate thyroid
diseases. During the early stages of embryonic development,
visceral endoderm gives rise to extra-embryonic endoderm.
Whereas, anterior deﬁnitive endoderm migrates to form the
primitive gut (foregut, midgut and hindgut). Follicular cells
develop from the anterior foregut endoderm and are clearly
different from C cells of neuroectodermal origin. Therefore,
thyroid cell lineages formed by ESC-derived endoderm could be
considered an in vitro experimental model adopted for the study
of thyroid development.28–30 Thyroid growth requires a complex
network of transcription factors, including Pax-8, thyroid transcrip-
tion factors 1 (TTF-1, also known as homeobox protein Nkx-2.1)
and 2 (TTF-2, also known as forkhead box protein E1, Foxe1), as
well as hematopoietically expressed homeobox protein HHEX
(Table 1). Each of these factors exhibits distinct roles within
different embryonic tissues, but their speciﬁc cooperation in
progenitor cells is fundamental to uniquely drive thyroid
organogenesis.31 Speciﬁcally, TTF-1 and Pax-8 are needed for
precursor survival, while TTF-2 promotes their migration. Mean-
while, HHEX works to maintain the expression of these three
factors and prevent differentiation.30 In addition, the surrounding
mesenchyme, contributes to expand the pool of thyroid cell
progenitors through the release of pro-epidermal growth factor
and basic ﬁbroblast growth factor (bFGF, or FGF-2).31,32 As
discussed below, the co-expression of TTF-1 and Pax-8, is an
essential event for cell commitment towards follicular cell fate.33
While, FGF and bone morphogenetic protein (BMP) signalling
pathways act in the early stages of thyroid development34 before
TSH/TSH-R and IGF/insulin signalling that promote the full
differentiation of follicular cells (Figure 4 and Table 1).35
In order to identify early and late markers of thyroid
development, several studies are being carried out using mouse
ESCs as a source of in vitro differentiating thyrocytes. Lin et al.36
demonstrated that mouse ESCs formed embryoid bodies that
upon differentiation, express a set of thyroid-speciﬁc markers,
such as Pax-8, thyroid peroxidase (TPO), Tg, sodium/iodide
cotransporter (NIS) and TSH-R. In absence of serum, these
differentiated cells did not express Tg. TSH treatment was
necessary to maintain Pax-8 and TSH-R expression during
embryoid body differentiation, but it was not sufﬁcient to express
Tg. This suggests that other factors, besides TSH, are required for
long-term maintenance and the maturation of thyrocytes.36 Later,
TSH and activin A, a transforming growth factor β (TGF-β) family
member, were proposed as important factors in endoderm
speciﬁcation and thyrocyte differentiation, while insulin and
IGF-I promoted the long-term maturation of thyrocytes expressing
Tg, NIS and TSH-R.37 According to these data, TTF-1, TTF-2, and Pax-8
can be considered speciﬁc markers of thyroid SC/progenitors, TSH-R
a marker of precursor cells, Tg, TPO and NIS markers of fully
differentiated thyroid follicles (Figure 4 and Table 1).
Recently, Antonica’s research group demonstrated the differ-
entiation of murine ESCs into the thyrocytic lineage, with the
Control
FTC
PTC
ATC
Figure 1. Epithelial thyroid cancer histotypes. Histochemical analysis
on parafﬁn-embedded sections of human thyroid gland control
(Control), FTC, PTC and ATC.
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formation of thyroid follicles, able to induce iodide
organiﬁcation.33 In particular, the simultaneous ectopic expression
of TTF-1 and Pax-8 induced the in vitro differentiation of mouse
ESCs into follicular cells. After treatment with TSH, these cells
showed molecular, morphological and functional characteristics of
thyroid follicles and were able to fulﬁl thyroid hormone deﬁcits
when transplanted orthotopically into an immunodeﬁcient
mouse.33 Pax-8 and TTF-1 co-expression is therefore required for
assembling the follicular cells into becoming a follicle-like
structure, as recently conﬁrmed.38
Longmire et al. demonstrated that the presence of activin A led
ESCs to differentiate into deﬁnitive endoderm, expressing fork-
head box protein A2 (Foxa2+). At this stage, if exposed to BMP and
activin/TGF-β signalling inhibitors (Noggin and SB431542, respec-
tively) for a speciﬁc amount of time, deﬁnitive endoderm was
shown to be directed towards the lung/thyroid competent
deﬁnitive endoderm, negative for forkhead box protein A3
(Foxa2+/Foxa3−). Hence, induction of BMP and FGF signalling by
exposing cells to high doses of FGF-2 combined with speciﬁc
factors (that is, BMP-4, Wnt3a, FGF-10, FGF-7, epidermal growth
factor and heparin), may promote the initial lineage speciﬁcation
of endodermal TTF-1+ thyroid primordial progenitors. The efﬁcient
induction of TTF1 into endodermal progenitors, is restricted by a
stage-speciﬁc and time-dependent inhibition of BMP and activin/
TGF-β signalling, followed by BMP reactivation and combined with
FGF signalling.34,39–41 D’Amour et al.42 reported similar results
using human cells, observing that in the presence of FGF-2 high-
dose activin A induced a massive differentiation of ESCs into
transcription factor SOX-17+/Foxa2+ deﬁnitive endodermal cells
(Figure 4 and Table 1). Interestingly, Onyshchenko et al.43 used
two methods in order to differentiate human ESCs in thyroid
follicular cells: (i) an one-step protocol that aims at a direct
differentiation through TSH stimulation by avoiding the inter-
mediate endoderm formation and (ii) a two-step protocol with an
intermediate passage in endodermal cells, which foresees the TSH
stimulation in combination with activin A and FGF-2. In both cases,
we were unable to obtain an efﬁcient generation of differentiated
cells that express speciﬁc thyroid markers. This suggests that,
molecular mechanisms involved in mouse and human differentia-
tion are different, and TSH by itself is not sufﬁcient to induce
thyrocyte-like cell differentiation in vitro.
The thyroid is a low proliferating gland, known for its self-
renewal ability.8,16 It has been suggested that follicle regeneration
is maintained by a pool of SCs that reside in the adult gland. ASCs,
estimated to be ~ 0.1% of all thyroid cells, are undifferentiated in a
quiescent or slow-cycling state and could replicate themselves to
Figure 2. Thyroid follicular cell. The main regulators of thyroid function are TSH signalling through cAMP-dependent pathway, and growth
GFs, acting via MAPK and PI3K/Akt signalling pathways. Alterations in key factors of these pathways (indicated in red) could lead to thyroid
transformation: gain-of-function, mutations in TSH-R and Gsα encoding genes could result in benign lesions such as hyperfunctional
adenomas. RAS and BRAF mutations in MAPK pathway are frequently observed in PTC. Genetic alterations in genes associated with the PI3K/
Akt pathway, i.e., PAX8 (40%) and TP53, are involved in FTC and ATC, respectively. The frequency of BRAFV600E in thyroid carcinomas is 50%.
Thyroid tumours have been found to have mutations in NRAS (4.6%) and HRAS (1.2%) codon 61. Mutations in TP53 occur in 6% of all thyroid
tumours, whereas the frequency of PTEN and PI3K mutations is 3%. Genetic alterations and mutation frequency reported are referred to http://
www.mycancergenome.org and http://cancer.sanger.ac.uk.
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Figure 3. Thyroid carcinogenesis model. The multistep carcinogenesis model suggests that undifferentiated thyroid carcinomas derive from
well-differentiated tumours via the sequential accumulation of genetic mutations and dedifferentiation process. According to the fetal cell
carcinogenesis model, thyroid cancer cells originate from the transformation of three types of fetal thyroid cells—thyroid stem cells,
thyroblasts and pro-thyrocytes, which would result in ATC, PTC and FTC. The CSC model assumes that only a small subset of cells possesses
the ability to trigger, reconstitute and sustain tumour growth.
Table 1. Cell markers of thyroid development
Cell specialisation Marker Function References
Thyroid competent
deﬁnitive endoderm
Transcription factor SOX-17 Transcription factor required for normal development of deﬁnitive
gut endoderm
32,37,39–43
Forkhead box protein A2 (Foxa2) Transcription factor involved in endoderm-derived organ
development
32,34,37,39–43,52
Thyroid primordial
progenitor
Paired box protein Pax-8 (Pax-8) Transcription factors that have a role in the regulation of thyroid-
speciﬁc genes (i.e., TG, TPO, TSHR), needed for the maintenance of
thyroid differentiation phenotype. Their co-expression is essential
for the survival and the speciﬁcation towards the thyroid cell type
18,29–34,36,38,41,55
TTF-1 or Homeobox protein Nkx-2.1 18,29–34,38,40,45,49–51
TTF-2 or Forkhead box protein E1 Transcription factor involved in thyroid gland organogenesis,
promoting cell migration
29–33
Hematopoietically expressed
homeobox protein HHEX
Transcription repressor involved in thyroid development; it
maintains gene expression of PAX8, TTF1 and TTF2 in the thyroid
primordium
30–32,34,40,41
Thyroid precursor TSH-R Central player in controlling thyroid cell metabolism through the
cAMP cascade
18,29,32–34,36–38,43,54,55
Thyrocyte Tg Precursor of the iodinated thyroid hormones T3 and T4 29,33,34,36–38,49,50,52–55
Sodium/iodide cotransporter
(NIS)
Symporter that regulates iodide uptake 18,29,33,36–38,43,54,55
TPO Enzyme acting in iodination and coupling of the tyrosine residues
in Tg to produce T3 and T4
18,29,36–38,43,51,54,55
Solid cell nest Tumour protein 63 (p63) Transcription factor implicated in epithelial morphogenesis
regulation; the ratio between ΔN/TA-type isoforms may regulate the
maintenance of the epithelial stem cell compartment
18,44–50,53
Abbreviations: Tg, thyroglobulin; TPO, thyroid peroxidase; TSH-R, thyrotropin receptor; thyroid transcription factor 1, TTF-1; thyroid transcription factor 2, TTF-2.
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preserve tissue turnover after damage.17 Embryonic remnants
have been identiﬁed in adult thyroid tissue as small clusters, the
solid cell nests (SCNs), which could represent a potential niche of
thyroid SCs deﬁned by the expression of tumour protein 63 (p63,
Table 1).30 SNC is composed of centrally located undifferentiated
p63− cells, and surrounded by p63+ cells with a basal/SC
phenotype clustered or structured within a single layer.44–46
Indeed, some of its stemness features have been demonstrated:
the self-renewal capability conferred via telomerase activity and
the differentiation potential in more cell types, due to high p63
and Bcl-2 expression.47,48 Reis-Filho et al.49 identiﬁed the SCNs as
structures composed of numerous main cells and rare C cells. Main
cells are notably characterised with basal/SC marker p63, basal
cytokeratins (excluding cytokeratin 20), and the carcinoembryonic
antigen. In contrast, C cells lack p63 and are immunoreactive to
differentiation markers, such as calcitonin and TTF-1.49 Hence, it
has been proposed that SCN main cells can be considered a pool
of multipotent SCs, involved in histogenesis and self-renewal of
both follicular and C cells.47 The potential stem role of SCN main
cells was supported by immunohistochemical proﬁle studies.44,50
Recently, Okamoto et al.51 supported the involvement of SCN in
thyroid regeneration, having observed a similar morphology in
irregular shaped follicles generated after a partial thyroidectomy
in mice. These cells were characterised as SC antigen 1 (SCA1)+/
BrdU+/β-gal/TTF-1−, and temporarily co-expressed cytokeratin
14.52 They evolve into functional follicles, which express TPO after
120 days, indicating that they consist of newly formed follicular
cells, but do not originate from differentiated thyrocytes.51,52
Considering the SCN as a source for both follicular and C cells,
the presence of three cell types has been hypothesised:
(i) progenitors of follicular cells, arisen from the base of the
foregut (endodermal origin); (ii) progenitors of C cells, which
originate from ultimobranchial bodies (neural crest origin); and (iii)
and the follicular and C bipotential progenitor cells.8
In 1992, Dumont et al.17 ﬁrst hypothesised the existence of ASCs
within the mature thyroid gland. Thomas et al. isolated a
population of ASCs from the goitre, characterised by the
co-expression of the octamer-binding protein 4 (Oct-4) stem
pluripotent marker, the transcription factor GATA-4 and hepato-
cyte nuclear factor 4-α (HNF-4-α) endodermal markers and Pax-8.
These SCs, negative for Tg, were not inﬂuenced by TSH
treatment.53 Fierabracci et al. obtained a CD34+/CD45– subpopu-
lation of cells with self-replicative potential from different human
thyroid specimens, characterised by their expression of the
pluripotent Oct-4 markers and homeobox transcription factor
Nanog (hNanog). Under appropriate culture conditions, these cells
were able to generate follicles with thyroid hormonal
production.54
Hoshi et al. identiﬁed a side population (SP) able to efﬂux the
vital dye Hoechst 33342 in a thyroid murine. It ranged from 0.3 to
1.4% of the total population and was highly enriched with
stem/progenitor cell activity. According to the expression of
hematopoietic markers used to deﬁne SC populations, SP cells
were separated into two cellular subsets, SP1 (CD45−/c-kit−/
SCA-1+) and SP2 (CD45−/c-kit−/SCA-1−). Both SP cells were
characterised by high expression levels of ATP-binding cassette
sub-family G member 2 and Oct-4, and by a low expression level
of thyroid differentiation markers. In particular, SP2 cells seem to
have progenitor characteristics because of their low TTF-1
and TSH-R expression that is in line with their involvement in
thyroid lineage commitment. Furthermore, the putative SC
marker nucleostemin was reported to be downregulated in
Figure 4. In vitro differentiation of thyroid follicular cells from ESC-derived endoderm. Blastocyst-derived ESCs form in vitro embryoid bodies
able to generate derivatives of the three germ layers. The embryoid bodies differentiate into deﬁnitive endoderm in presence of activin A, and
into thyroid competent deﬁnitive endoderm after exposition to inhibitors of BMP and activin A/TGF-β signalling. At the later stage, the
concomitant induction of BMP and FGF signalling, and TTF-1 and Pax-8 co-expression, results in the generation of thyroid primordial
progenitors. Thyroid precursors, derived from progenitor cells after TSH treatment, differentiate into Tg-expressing thyrocytes in presence of
insulin and IGF-I.
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undifferentiated thyroid cells.18 The SP selection method has also
been used to isolate ASCs in human thyroid. Lan et al. showed that
thyroid ASCs isolated from human goitres were able to
differentiate into thyroid cells and grow either in a monolayer or
embedded in collagen. Under the inﬂuence of TSH in a serum-
enriched medium, isolated ASCs differentiated into thyrocytes
expressing Pax-8, Tg, NIS and TPO. Moreover, when embedded in
collagen, they were able to uptake iodine in response to TSH.55
These results reinforce the reported observations regarding the
ability of goitre-derived ASCs, to differentiate into thyroid cells.
THYROID CANCER STEM CELLS
It is becoming increasingly evident that tumours are organised
hierarchically similarly to normal tissues, where a small subpopu-
lation named CSCs is responsible for cancer initiation and
progression. Assuming the involvement of SCs in thyroid
carcinogenesis, it is necessary to clarify the SCs’ dual role in the
initiation and propagation of a tumour. In cancer initiation, the
'cell-of-origin' concept explains how a normal cell acquires the ﬁrst
mutation able to kick-start the tumour (tumour initiating cells,
TICs). TICs constitute a tumour cell subset that sustains tumour
growth, but does not necessarily originate from the transforma-
tion of normal SCs.56 However, SCs are able to live for a long time,
undergo self-renewal and possess the key features required for
the acquisition of genetic or epigenetic changes leading to cancer
development.57 To recognise the cell-of-origin of neoplastic
transformation, it is helpful to ﬁrst enucleate the cellular hierarchy
present within the tumour tissue. Putative cells-of-origin are
committed progenitor or precursor cells, able to reacquire a SC-
like phenotype and functions upon genetic or epigenetic
reprogramming.58 Early progenitors, also known as transit
amplifying cells, are facilitated in the acquisition of modiﬁcations
that drive reprogramming, due to their elevated proliferative
capacity and undifferentiated state. Among the TIC population,
transit amplifying cells have a predominant role in primary tumour
formation, but only a small fraction of them shows detectable self-
renewal and metastasis-forming potential. However, initiation and
maintenance of the tumour seem to be dynamic processes,
characterised by the transition between the self-renewing and
transient amplifying phenotypes (Figure 5).59,60 CSCs are identiﬁed
due to their ability to self-renew and are represented by: (i) long-
term TICs (LT-TICs) able to maintain tumour formation after serial
xeno-transplantations and involved in metastasis formation; (ii)
delayed contributing TICs (DC-TICs), active only in secondary or
tertiary tumour xenografts (Figure 5).59 The peculiar feature of
CSCs concerns the pronounced tendency to undergo symmetric
division as compared with normal SCs. This drift is driven by
major genetic and epigenetic events conferring unlimited
lifespan and to CSCs, which are ultimately responsible for
tumour growth and progression.61 In studying CSCs in the
thyroid, several research groups have developed speciﬁc
methods to isolate TICs from this gland (Table 2). In this
overview, we do not take into consideration those studies or
single results obtained using ARO, NPA and KAT-4 cell lines,
being that they were found not to be of thyroid origin.62
Injecting putative CSCs into immunocompromised mouse
models63–65 and following the tumour development constitutes
an univocal way of testing their effective tumourigenicity.66 It has
been observed that serial transplantation led to an in vivo
selection of cells able to generate more aggressive tumours.67 In
particular, transplantations of cells, isolated from secondary and
tertiary xenografts, permit to deﬁne their long-term tumourigenic
potential, as well as their self-renewing ability (Figure 5).
High level of aldehyde dehydrogenase (ALDH) activity is present
in stem and progenitor cells, thus it has been used as a functional
marker for CSCs isolation in tumours.30,68 Todaro et al. showed
that PTC, FTC and ATC contain a small population of tumourigenic
cells with high ALDH activity and unlimited replication potential.
Expanded indeﬁnitely in vitro as tumour spheres, these ALDHhigh
cells contain 25–60% of the clonogenic cells able to generate
serial tumour xenografts. Interestingly, the highest percentage
(60%) of clonogenic cells present in ATC, deﬁned the cellular
subset endowed with a boosted self-renewal activity and a
tumourigenic and metastatic potential. This suggests that ATC
cells undergo multiple rounds of symmetric division.
In line with this, the injection of ALDHhigh cells derived from FTC
led to a moderately invasive tumour without distant metastasis.
Whereas, ALDHhigh cells derived from ATC, are able to invade
adjacent tissues and produce lymph nodes and lung metastasis
because of a strong constitutive activation of c-Met/Akt
pathways.63 Elevated ALDH activity was also identiﬁed in ATC cell
lines: 17–38% of ATC-8505C30 and 8–13% of SW173669 were
ALDHhigh.
hNanog, Oct-4 and transcription factor SOX-2 (encoded by
NANOG, POU5F1 and SOX2 genes, respectively) are transcription
factors that establish SC features through a pluripotent regulatory
network.70 Detection of high levels of these transcription factors,
together with low or absent markers of thyroid differentiation, can
help identify putative thyroid CSCs (Figure 6).30,63,64,71–73 Such
identiﬁcation can be supported by the analysis of biomarker
expression belonging to self-renewing control pathways, such as
Wnt/ β-catenin, Sonic hedgehog protein and Notch1 (classiﬁed
also as epithelial–mesenchymal transition (EMT)-inducing signal-
ling pathways).74 Malaguarnera et al.75 reported that the self-
renewal capacity of thyrospheres is also sustained by the over-
expression of the insulin receptor and IGF signalling pathway
genes (IGF-I receptor, IGF-I, IGF-II) promoting their volume, growth
and survival.
Recently, Ahn et al. identiﬁed a small percentage of CD44high/
CD24low cells with tumourigenic capability in the papillary TPC1
cell line, in six human primary PTCs and in four metastatic lymph
node specimens, as well as in two PTC-derived ATC samples.
Notably, CD44high/CD24low cells showed a higher Oct-4 expression
and lower differentiation marker expression than CD44high/
CD24high cells, together with the ability to form thyrospheroids.
However, no tumour was detected after the inoculation of
CD44high/CD24low human specimens into athymic Ncr-nu/nu
mice.65
Different research groups reported controversial results regard-
ing CD133 (also known as Prominin-1) in TC. In anaplastic KAT18
and FRO cell lines, Zito et al.76 did not ﬁnd CD133+ cells; Friedman
et al.71 identiﬁed CD133+ in 6.32% FRO cells, but not in the
papillary TPC cell line. Recently, Ke et al.77 described o5% CD133+
cells in papillary CG3 and follicular WRO and CGTH cell lines. By
using primary tumours, Malaguarnera et al.75 and Tseng et al.73
identiﬁed a CD133+ subpopulation in PTC samples, while it was
absent in thyroid spheres derived from PTC, FTC and ATC samples
analysed by Todaro’s research group.63 Immunohistochemical
examinations reported an elevated expression of CD133 in ATC
parafﬁn-embedded tissue sections,71,78 but only a low variable
expression in FTC and PTC adjacent to ATC samples.78 Besides the
inconsistencies in the reported results, another limit of this marker
is that its expression is greatly inﬂuenced by the cell cycle phase.79
SCs are enriched in the SP compartment. However, dye efﬂux is
not a characteristic common to all SCs, and this feature is not
limited only to the SC phenotype. This method seems to be
associated with a toxic effect on cells.80 Mitsutake et al.74 found a
very small portion of the SP in follicular WRO (0.02%) and
anaplastic FRO (0.1%) human cell lines, but not in papillary TPC1.
After sorting, these cells showed a higher clonogenic ability than
those referred as main population (MP), and were tumourigenic
after being injected into nude mice. The two subpopulations
showed a different gene expression proﬁle. Microarray experi-
ments revealed an upregulation of ABCG2, Wnt (MYC, JUN, FZD5)
and Notch1 pathway genes (HES1 and JAG1) in SP cells. Following
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10 days in vitro expansion, the SP cells reconstituted the full cell
population (both SP and MP). MP also generated a small SP, and
was tumourigenic in nude mice. This suggests that the SP subset
constitutes only a part of the entire CSC component. CSCs are
more numerous in the SP, but the two subsets are not identical.74
Zheng et al. identiﬁed 0.41–0.83% of the SP in ATC cell lines
(SW1736, 0.41%; C643, 0.52%; HTh74, 0.83%) expressing ATP-
binding cassette sub-family G member 2 and multidrug resistance
protein 1 transporters, which survived a doxorubicin treatment.
These cells showed a 10-fold higher clonality and higher invasive
features in comparison to the MP. In a 6 months treatment,
doxorubicin gradually killed the MP, yet the SP, enriched with
Oct-4+ CSCs, constituted 70% of resistant cells. The authors found
a composition of thyrospheres in 5% of the SP and 495% of the
MP by FACS analysis.72 The SP identiﬁed in TCs is then
characterised by an over-expression of stemness markers and
higher clonogenic ability, supported by thyrospheres formation
and reconstitution of the MP. Moreover, it displayed chemo-
resistance and tumourigenic potential when injected into
immunocompromised mice.
THYROID CSCs AND METASTASIS
As observed in the experimental xenograft assay described above,
CSCs possess the capacity to seed new tumours when implanted
in appropriate animal hosts. This is theoretically analogous to
tumour initiation by disseminating tumour cells (DTCs), whose
success depends on their ability to spawn an unlimited number of
daughter cells (Figure 4). In light of their motility, invasiveness and
resistance to apoptosis, CSCs are central players in tumour
recurrence and metastasis formation.81–83 This model is supported
by the expression of EMT markers in CSCs and by the activation of
SC markers in EMT-induced cells.84,85
DTCs are considered the major cause of metastatic disease,
chemo-resistance and recurrence, and are characterised by the
capacity to migrate from primary tumours to secondary sites.
Therefore, DTCs can exist for long time in a quiescent state called
dormancy, corresponding to the latent period between primary
tumour detection, treatment, recurrence and metastatic spread.86
The molecular mechanism, responsible for the transition
of DTCs from a dormant to a proliferative state, involves a
cross-talk between DTCs and the extracellular matrix. Matrix
Figure 5. Initiation and propagation of thyroid cancer. Tumour bulk consists of tumourigenic and non-tumourigenic cells. Tumourigenic cells
include TICs able to start the tumour; among these, long-term (LT-TIC) and DC-TIC maintain tumour formation after xenograft-transplantation
and have characteristics of cancer stem-like cells. Although transit amplifying cells massively contribute to tumour formation, they lack in self-
renewal and metastasis-forming features. Some TICs, such as LT-TICs and DC-TICs, are also responsible for tumour dissemination, a mechanism
regulated by EMT, whereas the inverse MET drives metastatic colonisation.
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metalloproteinases, secreted by stromal cells, induce the switch
from tumour dormancy to metastatic growth and vice versa, in
some cases through a permissive niche generation. Moreover,
integrin signalling regulation directs this mechanism through the
extracellular signal-regulated kinase ½ (ERK-1/2) and p38α/β
pathways; in particular, high ERK-1/2:p38 signalling ratio promotes
primary tumour proliferation and metastatic disease, whereas the
opposite determines cellular dormancy.86,87
It has become evident that aberrant activation of β-catenin
and c-Met is involved in TC progression.88 Data reported by
Todaro et al. indicated that Akt, c-Met and β-catenin activation
correlates with invasive behaviour of ATC SCs, together with the
complete loss of E-cadherin expression. Interestingly, targeted
silencing of Akt and c-Met expression, reduced Twist and Snail
expression, and abrogated thyroid CSC invasiveness and meta-
static capacity.63
Other studies identiﬁed EMT regulators in TC, with different
expression among histotypes. Hardy et al. showed decreased
E-cadherin expression in differentiated TCs when compared to
normal tissues. While SNAI1 and SNAI2 were aberrantly
transcribed and expressed in follicular (FTC-133), papillary
(BCPAP, K1), and anaplastic (CAL-62, 8305C) cell lines, as well
as in human cancer samples, in line with the lack of close
cellular contact.89 Vasko et al.90 observed an over-expression of
the mesenchymal marker vimentin in PTC human samples,
associated with invasion and lymph node metastasis. Moreover,
Riesco-Eizaguirre et al.91 reported an over-expression of TGF-β
at the invasive front of PTC, suggesting that PTC cells
need to undergo EMT and subsequently mesenchymal–
epithelial transition (MET), to produce metastasis. In another
study, Liu et al. found an intense expression of nestin, CD133
and CD44 and an absence of E-cadherin expression in ATC.
Table 2. Biological methods for thyroid CSCs isolation and characterisation
Isolation method Description Integrative assay References
Sphere-forming assay In serum-free non-adherent condition, it allows the puriﬁcation of
CSC population from differentiated thyrocytes and ﬁbroblast,
through a negative selection
Clonogenic assay; limiting-diluting
assay; colony-forming assay;
proliferation and division assay
55,63–65,69,72,73,75
Xenografts assay The injection of CSCs in immunodeﬁcient mice (NOD/SCID,
NSG, nude) led to a tumour formation. Serial transplantations
permit the selection of CSCs able to generate more aggressive
tumours
Lineage tracing; limiting-dilution
injections
63–65
ALDH activity
(ALDEFLUOR)
Isolate CSCs based on their elevated ALDH activity: ALDHhigh
cells metabolise their substrate in a ﬂuorescent dye that permits a
positive FACS selection
30,63,69
Stemness biomarkers FACS positive selection based on:
|SC transcription factors: hNanog, Oct-4, transcriptor factor
SOX-2 protein
|EMT-inducing pathways: Wnt, Notch1, Sonic hedgehog protein
|CD44+/CD24− phenotype
|CD133
FACS negative selection for
differentiation markers: TPO, Tg,
NIS, TSH-R
30,63–65,69,71–75,77,78
Side population Positive selection for drug-resistance based on ABCG2 and
ABCB1 activity; these transporters pump out the drug
rendering the dye efﬂux sensitive to verapamil (a Hoechst
33342 inhibitor)
18,72,74
Abbreviations: ALDH, aldehyde dehydrogenase; CSCs, cancer SCs; EMT, epithelial–mesenchymal transition; FACS, ﬂuorescence activated cell sorting;
NOD/SCID, non-obese diabetic/severe combined immunodeﬁciency; NSG, NOD scid gamma; SC, stem cells; Tg, thyroglobulin; TPO, thyroid peroxidase;
TSH-R, thyrotropin receptor.
Control FTC PTC ATC
A
LD
H
1/
2 
 
hN
an
og
Figure 6. Thyroid CSCs markers. Immunoﬂuorescence analysis of ALDH1/2 and hNanog in control, FTC, PTC and ATC. Arrow heads indicate
cells co-expressing ALDH1/2 and hNanog.
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Contrarily, PTC and FTC samples showed variability in CD133
and CD44 detection, and were negative for nestin, but positive
for E-cadherin.78
By tissue microarray analysis, Buehler et al. observed that only
ATC samples showed a high expression of Snail and Twist
associated to a lack of E-cadherin. Otherwise, PTC, FTC and
normal specimens were negative for Snail and Twist and, with
strong diffused immune reactivity to E-cadherin.92 Lan et al.
observed that HIF-1α induced invasive and metastatic properties
in follicular cells (FTC-133) through EMT, as conﬁrmed by the
downregulation of E-cadherin and upregulation of vimentin.
Moreover, it was observed that cells with an over-expression of
HIF1α shared stem-like cell features highlighting that EMT induction
was directly associated with increased CSC populations.84
Several lines of evidence also supported the cross-talk between
Twist and ID proteins. Kebebew et al.93 observed over-expression
of the DNA-binding protein inhibitor ID-1 in ATC tissues, reporting
that the inhibition of ID1 mRNA expression results in decreased
growth and reduction of Tg and NIS expression. Moreover,
Ciarrocchi et al.94 disclosed that in vivo ID-1 expression is
associated with aggressiveness and metastatic potential in non-
anaplastic tumours, whereas another member of the ID proteins,
ID-3 is downregulated in PTC and may be related to the TSH-
induced differentiating process.95
CONCLUSIONS AND FUTURE PERSPECTIVES
Evidence shows that many pathways underlying the properties
of SCs are involved in cancer initiation and progression. A defect
in DNA stability is the early event that occurs in tumour
transformation followed by a loss of tumour suppressor gene or
oncogene activation. Herewith, long-lived SCs rather than short-
lived differentiated cells could be the cell compartment in
which genetic alterations promote an advantage in clonal
propagation. Due to genetic alterations in thyroid cells bearing
embryogenesis-associated pathways, transformed SCs represent
the undisputed protagonists in the development of TC. In this
scenario, further insights into thyroid SC biology could bring to
light the molecular mechanisms driving transformation of
normal vs cancer SCs and may help design effective anti-
cancer strategies.
CONFLICT OF INTEREST
The authors declare no conﬂict of interest.
ACKNOWLEDGEMENTS
This work was supported by the Italian Association for Cancer Research (AIRC) to GS
(AIRC IG 12819). We thank Tatiana Terranova for her editorial assistance and all the
colleagues who actively contributed to the completion of this review.
REFERENCES
1 Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics.
CA Cancer J Clin 2011; 61: 69–90.
2 Kondo T, Ezzat S, Asa SL. Pathogenetic mechanisms in thyroid follicular-cell
neoplasia. Nat Rev Cancer 2006; 6: 292–306.
3 Rivera M, Ghossein RA, Schoder H, Gomez D, Larson SM, Tuttle RM.
Histopathologic characterization of radioactive iodine-refractory ﬂuorodeox-
yglucose-positron emission tomography-positive thyroid carcinoma. Cancer 2008;
113: 48–56.
4 Nikiforov YE, Nikiforova MN. Molecular genetics and diagnosis of thyroid cancer.
Nat Rev Endocrinol 2011; 7: 569–580.
5 Kroll TG, Sarraf P, Pecciarini L, Chen CJ, Mueller E, Spiegelman BM et al.
PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma [corrected].
Science 2000; 289: 1357–1360.
6 Hou P, Liu D, Shan Y, Hu S, Studeman K, Condouris S et al. Genetic alterations and
their relationship in the phosphatidylinositol 3-kinase/Akt pathway in
thyroid cancer. Clin Cancer Res 2007; 13: 1161–1170.
7 Lin RY. Thyroid cancer stem cells. Nat Rev Endocrinol 2011; 7: 609–616.
8 Gibelli B, El-Fattah A, Giugliano G, Proh M, Grosso E. Thyroid stem cells—danger
or resource? Acta Otorhinolaryngol Ital 2009; 29: 290–295.
9 Takano T, Amino N. Fetal cell carcinogenesis: a new hypothesis for better
understanding of thyroid carcinoma. Thyroid 2005; 15: 432–438.
10 Nikiforova MN, Nikiforov YE. Molecular diagnostics and predictors in
thyroid cancer. Thyroid 2009; 19: 1351–1361.
11 Sastre-Perona A, Santisteban P. Role of the wnt pathway in thyroid cancer. Front
Endocrinol (Lausanne) 2012; 3: 31.
12 Garcia-Rostan G, Tallini G, Herrero A, D'Aquila TG, Carcangiu ML, Rimm DL.
Frequent mutation and nuclear localization of beta-catenin in anaplastic thyroid
carcinoma. Cancer Res 1999; 59: 1811–1815.
13 Quiros RM, Ding HG, Gattuso P, Prinz RA, Xu X. Evidence that one subset of
anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF
and p53 mutations. Cancer 2005; 103: 2261–2268.
14 Hardin H, Montemayor-Garcia C, Lloyd RV. Thyroid cancer stem-like cells and
epithelial-mesenchymal transition in thyroid cancers. Hum Pathol 2013; 44:
1707–1713.
15 Nikiforova MN, Ciampi R, Salvatore G, Santoro M, Gandhi M, Knauf JA et al.
Low prevalence of BRAF mutations in radiation-induced thyroid tumors in
contrast to sporadic papillary carcinomas. Cancer Lett 2004; 209: 1–6.
16 Coclet J, Foureau F, Ketelbant P, Galand P, Dumont JE. Cell population kinetics in
dog and human adult thyroid. Clin Endocrinol 1989; 31: 655–665.
17 Dumont JE, Lamy F, Roger P, Maenhaut C. Physiological and pathological
regulation of thyroid cell proliferation and differentiation by thyrotropin and
other factors. Physiol Rev 1992; 72: 667–697.
18 Hoshi N, Kusakabe T, Taylor BJ, Kimura S. Side population cells in the mouse
thyroid exhibit stem/progenitor cell-like characteristics. Endocrinology 2007; 148:
4251–4258.
19 Zhang P, Zuo H, Nakamura Y, Nakamura M, Wakasa T, Kakudo K. Immuno-
histochemical analysis of thyroid-speciﬁc transcription factors in thyroid tumors.
Pathol Int 2006; 56: 240–245.
20 Takano T. Fetal cell carcinogenesis of the thyroid: theory and practice. Semin
Cancer Biol 2007; 17: 233–240.
21 Nikiforov Y, Gnepp DR. Pediatric thyroid cancer after the Chernobyl disaster.
Pathomorphologic study of 84 cases (1991-1992) from the Republic of Belarus.
Cancer 1994; 74: 748–766.
22 Jhiang SM, Sagartz JE, Tong Q, Parker-Thornburg J, Capen CC, Cho JY et al.
Targeted expression of the ret/PTC1 oncogene induces papillary thyroid carci-
nomas. Endocrinology 1996; 137: 375–378.
23 Vermeulen L, Sprick MR, Kemper K, Stassi G, Medema JP. Cancer stem cells—old
concepts, new insights. Cell Death Differ 2008; 15: 947–958.
24 Thomas D, Friedman S, Lin RY. Thyroid stem cells: lessons from normal devel-
opment and thyroid cancer. Endocr Relat Cancer 2008; 15: 51–58.
25 Inaba M, Yamashita YM. Asymmetric stem cell division: precision for robustness.
Cell Stem Cell 2012; 11: 461–469.
26 Yamashita YM, Yuan H, Cheng J, Hunt AJ. Polarity in stem cell division: asymmetric
stem cell division in tissue homeostasis. Cold Spring Harb Perspect Biol 2010; 2:
a001313.
27 Morrison SJ, Kimble J. Asymmetric and symmetric stem-cell divisions in devel-
opment and cancer. Nature 2006; 441: 1068–1074.
28 Le Douarin N, Fontaine J, Le Lievre C. New studies on the neural crest origin of the
avian ultimobranchial glandular cells–interspeciﬁc combinations and cytochem-
ical characterization of C cells based on the uptake of biogenic amine precursors.
Histochemistry 1974; 38: 297–305.
29 Van Vliet G. Development of the thyroid gland: lessons from congenitally hypo-
thyroid mice and men. Clin Genet 2003; 63: 445–455.
30 Klonisch T, Hoang-Vu C, Hombach-Klonisch S. Thyroid stem cells and cancer.
Thyroid 2009; 19: 1303–1315.
31 De Felice M, Di Lauro R. Thyroid development and its disorders: genetics and
molecular mechanisms. Endocr Rev 2004; 25: 722–746.
32 Fagman H, Nilsson M. Morphogenetics of early thyroid development. J Mol
Endocrinol 2011; 46: R33–R42.
33 Antonica F, Kasprzyk DF, Opitz R, Iacovino M, Liao XH, Dumitrescu AM et al.
Generation of functional thyroid from embryonic stem cells. Nature 2012; 491: 66–71.
34 Longmire TA, Ikonomou L, Hawkins F, Christodoulou C, Cao Y, Jean JC et al.
Efﬁcient derivation of puriﬁed lung and thyroid progenitors from embryonic
stem cells. Cell Stem Cell 2012; 10: 398–411.
35 Davies TF, Latif R, Minsky NC, Ma R. Clinical review: the emerging cell biology of
thyroid stem cells. J Clin Endocrinol Metab 2011; 96: 2692–2702.
36 Lin RY, Kubo A, Keller GM, Davies TF. Committing embryonic stem cells to
differentiate into thyrocyte-like cells in vitro. Endocrinology 2003; 144: 2644–2649.
37 Arufe MC, Lu M, Lin RY. Differentiation of murine embryonic stem cells to thyr-
ocytes requires insulin and insulin-like growth factor-1. Biochem Biophys Res
Commun 2009; 381: 264–270.
New insights into the thyroid cancer origin
M Zane et al
9
© 2015 Macmillan Publishers Limited Oncogene (2015) 1 – 11
12
38 Ma R, Latif R, Davies TF. Thyroid follicle formation and thyroglobulin expression in
multipotent endodermal stem cells. Thyroid 2013; 23: 385–391.
39 Green MD, Chen A, Nostro MC, d'Souza SL, Schaniel C, Lemischka IR et al.
Generation of anterior foregut endoderm from human embryonic and induced
pluripotent stem cells. Nat Biotechnol 2011; 29: 267–272.
40 Hannan NR, Fordham RP, Syed YA, Moignard V, Berry A, Bautista R et al.
Generation of multipotent foregut stem cells from human pluripotent stem cells.
Stem Cell Reports 2013; 1: 293–306.
41 Brafman DA, Moya N, Allen-Soltero S, Fellner T, Robinson M, McMillen ZL et al.
Analysis of SOX2-expressing cell populations derived from human pluripotent
stem cells. Stem Cell Reports 2013; 1: 464–478.
42 D'Amour KA, Agulnick AD, Eliazer S, Kelly OG, Kroon E, Baetge EE. Efﬁcient
differentiation of human embryonic stem cells to deﬁnitive endoderm.
Nat Biotechnol 2005; 23: 1534–1541.
43 Onyshchenko MI, Panyutin IG, Panyutin IV, Neumann RD. Stimulation
of cultured h9 human embryonic stem cells with thyroid stimulating
hormone does not lead to formation of thyroid-like cells. Stem Cells Int 2012;
2012: 634914.
44 Burstein DE, Nagi C, Wang BY, Unger P. Immunohistochemical detection of p53
homolog p63 in solid cell nests, papillary thyroid carcinoma, and hashimoto's
thyroiditis: A stem cell hypothesis of papillary carcinoma oncogenesis. Hum Pathol
2004; 35: 465–473.
45 Kusakabe T, Hoshi N, Kimura S. Origin of the ultimobranchial body cyst: T/ebp/
Nkx2.1 expression is required for development and fusion of the ultimobranchial
body to the thyroid. Dev Dyn 2006; 235: 1300–1309.
46 Ozaki T, Nagashima K, Kusakabe T, Kakudo K, Kimura S. Development of thyroid
gland and ultimobranchial body cyst is independent of p63. Lab Invest 2011; 91:
138–146.
47 Cameselle-Teijeiro J, Preto A, Soares P, Sobrinho-Simoes M. A stem cell role for
thyroid solid cell nests. Hum Pathol 2005; 36: 590–591.
48 Preto A, Cameselle-Teijeiro J, Moldes-Boullosa J, Soares P, Cameselle-Teijeiro JF,
Silva P et al. Telomerase expression and proliferative activity suggest a stem cell
role for thyroid solid cell nests. Mod Pathol 2004; 17: 819–826.
49 Reis-Filho JS, Preto A, Soares P, Ricardo S, Cameselle-Teijeiro J,
Sobrinho-Simoes M. p63 expression in solid cell nests of the thyroid: further
evidence for a stem cell origin. Mod Pathol 2003; 16: 43–48.
50 Rios Moreno MJ, Galera-Ruiz H, De Miguel M, Lopez MI, Illanes M, Galera-Davidson
H. Inmunohistochemical proﬁle of solid cell nest of thyroid gland. Endocrine
Pathol 2011; 22: 35–39.
51 Okamoto M, Hayase S, Miyakoshi M, Murata T, Kimura S. Stem cell antigen
1-positive mesenchymal cells are the origin of follicular cells during thyroid
regeneration. Plos One 2013; 8: e80801.
52 Ozaki T, Matsubara T, Seo D, Okamoto M, Nagashima K, Sasaki Y et al.
Thyroid regeneration: characterization of clear cells after partial thyroidectomy.
Endocrinology 2012; 153: 2514–2525.
53 Thomas T, Nowka K, Lan L, Derwahl M. Expression of endoderm stem cell markers:
evidence for the presence of adult stem cells in human thyroid glands. Thyroid
2006; 16: 537–544.
54 Fierabracci A, Puglisi MA, Giuliani L, Mattarocci S, Gallinella-Muzi M.
Identiﬁcation of an adult stem/progenitor cell-like population in the human
thyroid. J Endocrinol 2008; 198: 471–487.
55 Lan L, Cui D, Nowka K, Derwahl M. Stem cells derived from goiters in adults
form spheres in response to intense growth stimulation and require thyro-
tropin for differentiation into thyrocytes. J Clin Endocrinol Metab 2007; 92:
3681–3688.
56 Visvader JE. Cells of origin in cancer. Nature 2011; 469: 314–322.
57 Visvader JE, Lindeman GJ. Stem cells and cancer—the promise and puzzles. Mol
Oncol 2010; 4: 369–372.
58 Chaffer CL, Brueckmann I, Scheel C, Kaestli AJ, Wiggins PA, Rodrigues LO et al.
Normal and neoplastic nonstem cells can spontaneously convert to a stem-
like state. Proc Natl Acad Sci USA 2011; 108: 7950–7955.
59 Dieter SM, Ball CR, Hoffmann CM, Nowrouzi A, Herbst F, Zavidij O et al.
Distinct types of tumor-initiating cells form human colon cancer tumors and
metastases. Cell Stem Cell 2011; 9: 357–365.
60 Zeuner A, De Maria R. Not so lonely at the top for cancer stem cells. Cell Stem Cell
2011; 9: 289–290.
61 Shahriyari L, Komarova NL. Symmetric vs. asymmetric stem cell divisions: an
adaptation against cancer? Plos One 2013; 8: e76195.
62 Schweppe RE, Klopper JP, Korch C, Pugazhenthi U, Benezra M, Knauf JA et al.
Deoxyribonucleic acid proﬁling analysis of 40 human thyroid cancer cell lines
reveals cross-contamination resulting in cell line redundancy and misidentiﬁca-
tion. J Clin Endocrinol Metab 2008; 93: 4331–4341.
63 Todaro M, Iovino F, Eterno V, Cammareri P, Gambara G, Espina V et al.
Tumorigenic and metastatic activity of human thyroid cancer stem cells. Cancer
Res 2010; 70: 8874–8885.
64 Li W, Reeb AN, Sewell WA, Elhomsy G, Lin RY. Phenotypic characterization of
metastatic anaplastic thyroid cancer stem cells. Plos One 2013; 8: e65095.
65 Ahn SH, Henderson YC, Williams MD, Lai SY, Clayman GL. Detection of thyroid
cancer stem cells in papillary thyroid carcinoma. J Clin Endocrinol Metab 2014; 99:
536–544.
66 Ailles LE, Weissman IL. Cancer stem cells in solid tumors. Curr Opin Biotechnol
2007; 18: 460–466.
67 Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, Jones DL et al. Cancer stem
cells—perspectives on current status and future directions: AACR Workshop on
cancer stem cells. Cancer research 2006; 66: 9339–9344.
68 Marcato P, Dean CA, Giacomantonio CA, Lee PW. Aldehyde dehydrogenase: its
role as a cancer stem cell marker comes down to the speciﬁc isoform. Cell Cycle
2011; 10: 1378–1384.
69 Carina V, Zito G, Pizzolanti G, Richiusa P, Criscimanna A, Rodolico V et al. Multiple
pluripotent stem cell markers in human anaplastic thyroid cancer: the putative
upstream role of SOX2. Thyroid 2013; 23: 829–837.
70 Rodda DJ, Chew JL, Lim LH, Loh YH, Wang B, Ng HH et al. Transcriptional
regulation of nanog by OCT4 and SOX2. J Biol Chem 2005; 280: 24731–24737.
71 Friedman S, Lu M, Schultz A, Thomas D, Lin RY. CD133+ anaplastic thyroid cancer
cells initiate tumors in immunodeﬁcient mice and are regulated by thyrotropin.
Plos One 2009; 4: e5395.
72 Zheng X, Cui D, Xu S. Brabant G, Derwahl M. Doxorubicin fails to eradicate cancer
stem cells derived from anaplastic thyroid carcinoma cells: characterization of
resistant cells. Int J Oncol 2010; 37: 307–315.
73 Tseng LM, Huang PI, Chen YR, Chen YC, Chou YC, Chen YW et al. Targeting signal
transducer and activator of transcription 3 pathway by cucurbitacin I diminishes
self-renewing and radiochemoresistant abilities in thyroid cancer-derived CD133
+ cells. J Pharmacol Exp Ther 2012; 341: 410–423.
74 Mitsutake N, Iwao A, Nagai K, Namba H, Ohtsuru A, Saenko V et al.
Characterization of side population in thyroid cancer cell lines: cancer stem-like
cells are enriched partly but not exclusively. Endocrinology 2007; 148: 1797–1803.
75 Malaguarnera R, Frasca F, Garozzo A, Giani F, Pandini G, Vella V et al. Insulin
receptor isoforms and insulin-like growth factor receptor in human follicular cell
precursors from papillary thyroid cancer and normal thyroid. J Clin Endocrinol
Metab 2011; 96: 766–774.
76 Zito G, Richiusa P, Bommarito A, Carissimi E, Russo L, Coppola A et al. In vitro
identiﬁcation and characterization of CD133(pos) cancer stem-like cells in
anaplastic thyroid carcinoma cell lines. Plos One 2008; 3: e3544.
77 Ke CC, Liu RS, Yang AH, Liu CS, Chi CW, Tseng LM et al. CD133-expressing thyroid
cancer cells are undifferentiated, radioresistant and survive radioiodide therapy.
Eur J Nucl Med Mol Imaging 2013; 40: 61–71.
78 Liu J, Brown RE. Immunohistochemical detection of epithelialmesenchymal
transition associated with stemness phenotype in anaplastic thyroid carcinoma.
Int J Clin Exp Pathol 2010; 3: 755–762.
79 Sun Y, Kong W, Falk A, Hu J, Zhou L, Pollard S et al. CD133 (prominin) negative
human neural stem cells are clonogenic and tripotent. Plos One 2009; 4: e5498.
80 Golebiewska A, Brons NH, Bjerkvig R, Niclou SP. Critical appraisal of the side popu-
lation assay in stem cell and cancer stem cell research. Cell Stem Cell 2011; 8: 136–147.
81 Hollier BG, Evans K, Mani SA. The epithelial-to-mesenchymal transition and cancer
stem cells: a coalition against cancer therapies. J Mammary Gland Biol Neoplasia
2009; 14: 29–43.
82 Raimondi C, Gianni W, Cortesi E, Gazzaniga P. Cancer stem cells and epithelial-
mesenchymal transition: revisiting minimal residual disease. Curr Cancer Drug
Targets 2010; 10: 496–508.
83 Chaffer CL, Weinberg RA. A perspective on cancer cell metastasis. Science 2011;
331: 1559–1564.
84 Lan L, Luo Y, Cui D, Shi BY, Deng W, Huo LL et al. Epithelial-mesenchymal
transition triggers cancer stem cell generation in human thyroid cancer cells.
Int J Oncol 2013; 43: 113–120.
85 Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY et al. The epithelial-
mesenchymal transition generates cells with properties of stem cells. Cell 2008;
133: 704–715.
86 Paez D, Labonte MJ, Bohanes P, Zhang W, Benhanim L, Ning Y et al. Cancer
dormancy: a model of early dissemination and late cancer recurrence. Clin Cancer
Res 2012; 18: 645–653.
87 Sosa MS, Avivar-Valderas A, Bragado P, Wen HC, Aguirre-Ghiso JA. ERK1/2 and
p38alpha/beta signaling in tumor cell quiescence: opportunities to control dor-
mant residual disease. Clin Cancer Res 2011; 17: 5850–5857.
88 Cassinelli G, Favini E, Degl'Innocenti D, Salvi A, De Petro G, Pierotti MA et al.
RET/PTC1-driven neoplastic transformation and proinvasive phenotype of
human thyrocytes involve Met induction and beta-catenin nuclear translocation.
Neoplasia 2009; 11: 10–21.
89 Hardy RG, Vicente-Duenas C, Gonzalez-Herrero I, Anderson C, Flores T, Hughes S
et al. Snail family transcription factors are implicated in thyroid carcinogenesis.
Am J Pathol 2007; 171: 1037–1046.
New insights into the thyroid cancer origin
M Zane et al
10
Oncogene (2015) 1 – 11 © 2015 Macmillan Publishers Limited
13
90 Vasko V, Espinosa AV, Scouten W, He H, Auer H, Liyanarachchi S et al. Gene
expression and functional evidence of epithelial-to-mesenchymal transition in
papillary thyroid carcinoma invasion. Proc Natl Acad Sci USA 2007; 104:
2803–2808.
91 Riesco-Eizaguirre G, Rodriguez I, De la Vieja A, Costamagna E, Carrasco N, Nistal M
et al. The BRAFV600E oncogene induces transforming growth factor beta
secretion leading to sodium iodide symporter repression and increased malig-
nancy in thyroid cancer. Cancer Res 2009; 69: 8317–8325.
92 Buehler D, Hardin H, Shan W, Montemayor-Garcia C, Rush PS, Asioli S et al.
Expression of epithelial-mesenchymal transition regulators SNAI2 and TWIST1 in
thyroid carcinomas. Mod Pathol 2013; 26: 54–61.
93 Kebebew E, Peng M, Treseler PA, Clark OH, Duh QY, Ginzinger D et al. Id1 gene
expression is up-regulated in hyperplastic and neoplastic thyroid tissue and
regulates growth and differentiation in thyroid cancer cells. J Clin Endocrinol
Metab 2004; 89: 6105–6111.
94 Ciarrocchi A, Piana S, Valcavi R, Gardini G, Casali B. Inhibitor of DNA binding-1
induces mesenchymal features and promotes invasiveness in thyroid tumour
cells. Eur J Cancer 2011; 47: 934–945.
95 Deleu S, Savonet V, Behrends J, Dumont JE, Maenhaut C. Study of gene
expression in thyrotropin-stimulated thyroid cells by cDNA expression array: ID3
transcription modulating factor as an early response protein and tumor marker in
thyroid carcinomas. Exp Cell Res 2002; 279: 62–70.
New insights into the thyroid cancer origin
M Zane et al
11
© 2015 Macmillan Publishers Limited Oncogene (2015) 1 – 11
14
 Chapter 2 
 
 
 
In vitro Human Embryonic Stem Cells differentiation: a reliable model for 
thyroid carcinogenesis  
 
 
Emanuela Scavo, Miriam Gaggianesi, Laura Rosa Mangiapane, Tiziana Apuzzo, 
Antonina Benfante, Simone Di Franco,  Matilde Todaro and Giorgio Stassi 
 
 
Manuscript in preparation 
 
  
15
 Abstract 
Stem cells are unspecialized cells with the ability to perpetuate themselves for long 
periods and give rise to specialized cell types. Although it was postulated that tumor 
may often originate from stem cells transformation, the target cell of transforming 
mutations is still unknown. It is becoming increasingly clear that distinct cancer cells 
within an organ may derive from different cells-of-origin able to acquire the first 
driven mutation giving rise to a broad spectrum of cancer histotypes. Here we present 
an innovative and reliable experimental approach to study the cellular hierarchy of  
normal thyroid tissue in order to identify the target cells of transforming mutations 
underling the thyroid carcinogenesis. Identification of the cells-of-origin and tumor-
related driven mutations might be an essential prerequisite to design innovative 
therapeutic approach. 
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 2.1 Introduction 
Thyroid cancer (TC) is the most common endocrine malignancy including different 
histotypes that range from differentiated carcinomas with good prognosis to the lethal 
undifferentiated disease. Papillary TC (PTC) and follicular TC (FTC) referred as well-
differentiated thyroid cancer, and anaplastic TC (ATC), an undifferentiated subtype of 
thyroid cancer, arise from follicular cells. PTC and FTC are indolent carcinomas and 
can be treated via surgical resection in combination with radioactive iodine and l-
thyroxine therapy. The loss expression of typical thyroid differentiation markers such 
as thyroid-stimulating hormone receptor (TSH-R), thyroglobulin (Tg), thyroid 
peroxidase (TPO), and sodium iodide symporter (NIS), defines the characteristics of 
ATC, which has a poor prognosis with no effective therapy. Alterations of key factors 
in MAPK and PI3K/Akt signalling pathways have been shown to be involved in the 
development of thyroid carcinoma. RET/PTC rearrangements and BRAF or RAS point 
mutations are frequently observed in PTC and are considered mutually exclusive. The 
most common genetic alterations in FTC and ATC are PAX8/PPARγ rearrangements 
and TP53 point mutations, respectively (1-7). 
Recent advances in the field of stem cell biology led to the acquisition of new insights 
into the molecular mechanisms underlying disease processes. Stem cells (SCs) have 
self-renewal capability and possess the key features required for the acquisition of 
genetic or epigenetic changes involved in cancer development (6-11). Research 
findings supported the concept that tumors are organized in a hierarchy of different 
tumor cells and only a sub-population with stem-cell like characteristics, called 
Cancer stem cells (CSCs), is responsible for tumor initiation and progression. Cancer 
heterogeneity can be impacted by several determinants influencing tumor progression 
and therapeutic response. Strong evidence is emerging that tumor of a single patient is 
a mixture of genetically distinct clones. The driver mutations within each clone can 
influence the tumor features in each in one's own way contributing to functional 
heterogeneity. At the same time, non-genetic determinants, including developmental 
pathways and epigenetic modifications contribute to functional heterogeneity. Non-
genetic determinants, normally involved in the  maintenance of normal tissue stem 
cell hierarchies, bring to hierarchically organized tumor tissues where CSCs uniquely 
sustain the malignant growth (12-19). According to this hypothesis, a new view of TC 
was proposed describing it as a stem cell disease. The CSCs model suggests that only 
a subpopulation of thyroid cancer cells, with self-renewal ability, was able to 
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 differentiate into diverse cancer cell types that can reconstitute and sustain tumor 
growth. These cells also mediate metastasis and are refractory to chemo- or radiation 
therapy (20-23). In order to understand the molecular mechanisms involved in thyroid 
tumorigenesis  and chemotherapy resistance, considerable research efforts have been 
addressed to identify and isolate thyroid CSCs.  
Todaro et al., showed that thyroid cancer tissues derived from PTC, FTC and ATC, 
contain a small population of CSCs identifiable through their high ALDH activity and 
unlimited self-renewal ability. These ALDHhigh cells can be expanded indefinitely in 
vitro as tumor spheres, and when orthotopically injected into the thyroid gland of 
immunocompromised mice can be able to generate serial tumor xenografts, 
reproducing the phenotypic characteristics of the parental tumors (24). 
Although it is widely assumed that tumor phenotype is influenced by genetic lesions, 
it is becoming increasingly clear that distinct cancers within an organ  may originate 
from cells at different differentiation stages giving rise to several cancer histotypes. 
According to this new idea, the cell-of-origin concept explains how an early precursor 
cell or a more committed cell could acquire the first driven mutation able to initiate 
the tumor. The cell-of-origin and CSC models are not mutually exclusive but 
cooperate to determine tumor phenotype by different cellular and molecular 
mechanisms (12-13). The existence of several differentiation degrees led to the 
assumption that a pool of SCs at different differentiation stages, prone to gain 
mutations, is responsible for thyroid cancer initiation and progression. A novel 
hypothesis about thyroid carcinogenesis posits that thyroid cancer cells derive from 
the remnants of fetal cells. Regarding to this theory, thyroid cancer cells would be 
generated from transformation of three types of fetal thyroid cells, thyroid SCs 
(TSCs), thyroblasts and prothyrocytes, which would result in ATC, PTC and FTC, 
respectively (21, 25). 
Since the tumor bulk is characterized by cells at diverse differentiation stages and 
assuming the involvement of SCs in thyroid carcinogenesis, it was necessary to clarify 
the SCs’ dual role in tumor initiation and propagation. With the aim to cross the 
difficulties in purification of cell compartments at diverse stages of differentiation, in 
the present study we generated TSCs, thyroblasts and prothyrocytes from human 
embryonic stem cells (hESCs) (26-34). As already described in detail in Chapter 1, 
human thyroid development requires a network of transcription factors that acts to 
drive thyroid organogenesis. The thyroid gland consists of two endocrine cell types, 
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 the thyroid follicular cells (TFCs) that produce the thyroid hormones T3 and T4 and 
the C-cells that produce calcitonin (35). During thyroid organogenesis, TTF-1 and 
Pax-8 co-expression in a small group of ventral foregut endodermal cells is an 
essential event for cell commitment towards a TFC fate. (24, 31). The hESC-derived 
endoderm transition into thyroid progenitors is finely regulated by the time-dependent 
BMP and activin/TGF-β signaling pathway inhibition, followed by BMP and FGF 
signaling reactivation (31). Here we speculate that the in vitro differentiation of 
hESCs into thyroid cells represents an innovative and reliable experimental approach 
to study the cellular hierarchy of normal thyroid tissue in order to provide new ground 
for the identification of cells-of-origin and tumor-related driven mutations involved in 
thyroid carcinogenesis. Our intent is to prove that the different thyroid tumor 
histotypes are determined by distinct genetic alterations occurring within the same 
target cells, that are TCSs, or specific mutations taking place in distinct cells-of-
origin, at different differentiation stages of the thyroid tissue (Fig. 1A and 1B) (6). 
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Figure 1. Tumor heterogeneity models. (A) In genetic mutation model, different genetic alterations
occurring within the same target cells result in various tumor phenotypes. (B) In the cell-of-origin
model, different tumor phenotypes derive from specific genetic alterations taking place in distinct cell
populations that serve as cell-of-origin.
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 2.2 Materials and Methods 
2.2.1 Tissues, cell culture, clonogenic and invasion assays  
Thyroid cancer tissues were obtained at the time of thyroidectomy from patients 
affected by PTC, FTC and ATC in accordance with the ethical standards of the 
institutional committee responsible for human experimentation. Normal thyroid 
tissues were obtained from goiters. Diagnosis was based on the histological analysis 
of thyroid specimens determining size, tumor progression and the involvement of 
regional lymph nodes. Staging was established according to the UICC TNM 
classification of malignant tumor (ICD- O C73) (UICC TNM. Classification of 
Malignant Tumors; 7th Edition. New York: Wiley Liss 2002). Normal and tumor 
thyroid cells were purified from fresh tissues as described in ref. (24). In these 
conditions, differentiated cancer cells and normal cells will die by anoikis, while 
CSCs will grow as sphere aggregates. For clonogenic assay cells were plated on ultra 
low-adhesion 96-well plates at a concentration of a single cell per well in presence of 
stem cell medium containing bFGF (20ng/ml, NOVUS Biologicals) and EGF 
(10ng/ml, NOVUS Biologicals). Wells containing either none or more than one cell 
were excluded for the analysis. Cell migration was measured using growth factor–
depleted Matrigel-coated (BD Biosciences) transwell inserts. Dissociated sphere cells 
(1.5 × 103) were plated onto Matrigel-coated transwells with 8μm pore size. DMEM 
supplemented with 5% of human serum was plated in the lower compartment of the 
transwell. After plating, migrated cells were counted up to 72 hours. 
hESCs culture and differentiation 
hESCs (line WA26), obtained from National Stem Cell Bank (Madison, WI), were 
maintained in the undifferentiated state in feeder-free culture conditions using 
Essential 8TM Medium (Gibco by Thermo Fisher Scientific) on 6-well plates coated 
with hESCs qualified Matrigel as recommended by manufacturer’s instructions 
(Corning). The culture medium was changed daily, and cells were passaged every 
four to five days at ratios of 1:2 to 1:4. Cells were cultured at 37°C in a 5% CO2 
humidified incubator. Differentiation of hESCs into definitive endoderm was 
performed using STEMdiff™ Definitive Endoderm Kit following the manufacturer’s 
instructions (Stemcell technologies). Day 5 hESC-derived endoderm cells, plated onto 
hESCs qualified matrigel-coated plates, were cultured for 24 hours in Serum free 
differentiation medium (cSFDM) containing IMDM 375ml, Ham’s F12 125ml, B-27 
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 supplement 5ml (Gibco, Thermo Fischer Scientific), N-2 supplement 2.5ml (Gibco, 
Thermo Fischer Scientific), BSA 7.5% in PBS 3.3ml (USBiological), 200mM L-Glut 
-1ml (EuroClone) and Ascorbic Acid 1ml of stock 5mg/ml (Sigma), supplemented 
with 100ng/ml Noggin (R&D System) and 10μM SB431542 (Selleckchem). After 24 
hours the media was switched to TTF-1 induction media cSFDM supplemented with 
100ng/ml Wnt3a (R&D System), 10ng/ml KGF (Peprotech), 10ng/ml hFGF10 
(Peprotech), 10ng/ml BMP4 (R&D System), 20ng/ml hEGF (NOVUS Biologicals), 
500ng/ml FGF2 (NOVUS Biologicals) and 100ng/ml Heparin Sodium Salt (Sigma). 
On day 22, where indicated in the text, the media was switched to thyroid maturation 
media consisted of Ham’s F12  supplemented with 15mM HEPES (pH 7.4), 0.8mM 
CaCl2, 0.25% BSA, 5µg/ml insulin, 5µg/ml  transferrin, 5ng/ml Naselenite (BD 
Biosciences), 100 U/mL TSH (Sigma), 50ng/mL IGF1 (NOVUS Biologicals), 100 
µM NaI. 
2.2.2 Flow cytometry  
Freshly isolated hESCs (Day 0) and definitive endoderm (Day 5) were stained with 
conjugated antibodies against  SOX-2-ALEXA FLUOR 488 (245610, mouse IgG2a, BD 
Biosciences), Nanog-ALEXA FLUOR 488 (N31-355, mouse IgG1k, BD Biosciences), 
SOX-17-ALEXA FLUOR 488 (P7-969, mouse IgG1k, BD Biosciences), Oct-3/4-PE 
(40/OCT3, mouse IgG1k, BD Biosciences), Foxa2-PE (N17-280, mouse IgG1k, BD 
Biosciences), CXCR-4-PE (12G5, mouse IgG2a, R&D Systems) or with purified 
primary TTF-1 (SPT24, mouse IgG1k; Leica Biosystem), TSH-R (4C1, mouse IgG2a; 
Abcam), TPO (EPR5380, rabbit IgG; Abcam), Tg (EPR9730, rabbit IgG; Abcam), 
NIS (SPM186, mouse IgG1; Abcam), Pax8 (goat polyclonal, IgG; Abcam) and c-Kit 
(T595, mouse IgG1k; Leica Biosystem). Then, cells were labeled with goat, rabbit 
and/or anti-mouse IgG FITC secondary antibody (Invitrogen). Specific corresponding 
isotype matched antibodies were used as negative controls. Samples were acquired 
using a FACS ARIA (BD Biosciences) flow cytometer. All data were analyzed using 
FlowJo software (Tree Star). 
2.2.3 Istochemistry and Immunofluorescence 
Histochemical is performed on 5-μm-thick paraffin-embedded sections of thyroid 
specimens. For H&E staining slides were stained for 1 min in hematoxilin, washed in 
water and then exposed for 30 sec to eosin. Stained sections were dehydrated and 
mounted in synthetic resin. For immunofluorescence, cytospins of hESCs (Day 0), 
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 definitive endoderm (Day 5), thyroid competent definitive endoderm (Day 6), 
thyreoblasts (Day 22), prothyrocytes (Day 25) and follicle (day 32) were fixed with 
2% paraformaldehyde, permeabilized with 0.1% Triton X-100 and exposed overnight 
at 4°C to antibodies against to SOX-2 (245610, rabbit polyclonal, IgG polyclonal; 
Stemgent), Nanog (N17, goat IgG; Santa Cruz Biotechnology), Oct-3/4 (C-10, mouse 
IgG2b; Santa Cruz Biotechnology), Foxa2 (N17-280, mouse IgG1k; BD Biosciences), 
SOX-17 (P7-969, mouse IgG1k; BD BD Biosciences), TTF-1 (SPT24, mouse IgG1k; 
Leica Biosystem), TSH-R (4C1, mouse IgG2a; Abcam), TPO (EPR5380, rabbit IgG; 
Abcam), Tg (EPR9730, rabbit IgG; Abcam), NIS (SPM186, mouse IgG1; Abcam), 
Pax8 (goat polyclonal, IgG; Abcam), cytocheratin 19 (B170, NCL-CK19, Novocastra) 
and c-Kit (T595, mouse IgG1k; Leica Biosystem). Cells were then labeled with FITC 
or rhodamine red–conjugated secondary antibodies (Invitrogen) plus RNase 
(200μg/mL; Sigma). Counterstaining was performed using Toto3 iodide (642/660; 
Invitrogen). 
2.2.4 microRNA expression analysis 
Total RNA was extracted using a TRIzol® Reagent solution (Ambion) following 
manufacturer’s instructions and microRNA expression analysis was performed by 
Megaplex pools protocol specific for a set of 384 microRNAs (pool A) as 
recommended by manufacturer’s instructions (Applied Biosystems). The relative 
quantification of microRNA expression was calculated using the equivalent Ct values 
where the original Ct values are projected to 100% target efficiency. All the 
experiments were normalized using global normalization method (39). microRNA 
arrays were performed for hESCs (Day 0), definitive endoderm (Day 5), thyroid 
competent definitive endoderm (Day 6), thyreoblasts (Day 22) and prothyrocytes 
(Day 25). At least 2 replicates were run for each sample. microRNAs with 2 fold 
changes were considered for analysis. 
2.2.5 Production of lentiviral particles and infection 
BRAFV600E cDNA with 5'- and 3' cohesive ends was subcloned at XhoI and EcoRV 
sites, while RET/PTC1 cDNA at XbaI and EcoRV. TP53R248Q cDNA was 
subcloned at XhoI site. Gene transfer was performed using a TWEEN lentiviral vector 
containing green fluorescent protein (GFP) and red fluorescent protein (RFP) as 
reporter gene. Transfection of packaging human embryonic kidney cell line HEK-
293T was assessed using FuGENE 6 Reagent (Roche) and following the 
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 manufacturer’s instructions. Lentiviral supernatants were collected following 48 hours 
transfection and filtered with a 45μm mesh. Then, normal thyroid stem cells were 
exposed to 1mL of viral supernatant of BRAFV600E, RET/PTC1 or TP53R248Q for 
40 min by centrifugation at 800 rpm, in the presence of 8μg/μL of polybrene to 
improve infection efficiency. Infection was repeated twice and efficiency of gene 
delivery was verified monitoring GFP and/or RFP expression.  
2.2.6 Animal model 
To evaluate the tumorigenicity and metastatic potential dissociated normal 
thyrospheres as well as those transduced with lentiviral vectors coding for RET/PTC1, 
BRAV600E, p53R248Q (5x105) were injected subcutaneously with Matrigel GF 
reduced (BD Biosciences) at a 1:1 ratio in a total volume of 100 μL. Tumor size was 
calculated once a week up for to 10 weeks according to the following formula: (π/6) x 
larger diameter x (smaller diameter)2. 
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 2.3 Results and Discussion 
2.3.1 Oncogenes orchestrating the thyroid stem cells transformation 
A better knowledge of the genetic alterations which occur in SCs leading to CSCs 
transformation may provide unique signatures for the development of more effective 
therapeutic strategies. In our previous study, we investigated whether self-renewal 
capacity is directly correlated with the most common genetic alterations in thyroid 
cancer. For this purpose, we generated a single cell cloning assay for TSCs isolated 
from goiters and transduced with lentiviral vectors coding for R ET/PTC1, 
BRAFV600E, and/or mutant TP53 (6) in order to determine whether these genetic hits 
might directly influence the self-renewal capacity (Fig. 2A and 2B). In accordance 
with the clonogenic potential detected in thyroid CSCs (24), we have interestingly 
noticed that the exogenous expression of BRAFV600E is associated with a lower 
clonogenicity than RET/PTC1 rearrangement and mutant p53, while combination of 
BRAFV600E and mutant TP53, which characterize the aggressive ATC histotype, is 
associated to the highest clonogenic activity (Fig. 2A and 2B). Furthermore, TSCs, 
after exogenous expression of RET/PTC1, BRAFV600E, and/or mutant TP53 showed 
a higher migration capacity than the control TSCs in the invasion assay analysis (Fig. 
2C and 2D). In particular, the most invasive cells were those bearing BRAFV600E 
plus mutant TP53 (Fig. 2C and 2D) . These results resembling the behavior observed 
on CSCs freshly isolated from ATC, PTC and FTC patients bearing the above 
mentioned mutations (Fig. 2A, 2B, 2C and 2D) (24).    
In order to evaluate the ability to initiate tumor development in recipient animals, a 
prerequisite of putative CSCs, it has been investigated the in vivo tumorigenic 
capacity of TSCs transduced with the indicated oncogenes by subcutaneous injection 
in NOD/SCID mice (Fig. 2E). Interestingly, macroscopic examination of xenografts 
removed after 10 weeks showed that TSCs overexpressing RET/PTC1 rearrangement 
or mutant TP53 alone were tumorigenic and TSCs bearing BRAFV600E plus mutant 
TP53 retain the highest tumorigenic capacity (Fig. 2E). Thus, our preliminary data 
suggest that combined genetic alterations sustain the growth of a tumor cell subset 
with CSC peculiarities. This population, characterized by unlimited lifespan, not 
necessarily originate from the transformation of normal SCs but could likely derive 
from well-differentiated tumor cells via the sequential accumulation of genetic 
mutations and de-differentiation process (6-7).  
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Figure 2. Oncogenes drive transformation of TSCs in tumorigenic cells. (A) Clonogenic assay of
TSCs isolated from goiters and trasduced with control empty lentiviral vector (EV), and lentiviral vector
coding for TP53mut, BRAFV600E, RET/PTC1 and TP53mut/BRAFV600E. (B) Clonogenic assay of
TSCs isolated from goiters (Nthy, control) and CSCs isolated from ATC, PTC and FTC specimes. (C)
Invasion assay of TSCs isolated from goiters and trasduced with EV and oncogens above mentioned. (D)
Invasion assay of TSCs isolated from goiters (Nthy, control) and CSCs isolated from ATC, PTC and FTC
specimes. (E) Size of tumors developed following subcutane injection of TSCs isolated from goiters and
trasduced with EV and oncogens above mentioned.
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 2.3.2 The time-dependent BMP and activin/TGF-β signaling inhibition renders 
hESC-derived endodermal cells competent to differentiate into thyroid-like cells 
Although SCs, with their unique self-renewal potential, are considered the favored 
candidates for sequential accumulation of genetic alterations required for tumor 
transformation, any cell with proliferative capacity, within the hierarchy in a normal 
tissues, could be considered a cell-of-origin able to initiate a tumor. The growing body 
of experimental evidence has revealed that an accumulation of genetic alterations in 
tissue-resident stem cells or in their more committed progenies may result in their 
malignant transformation. According to this theory, thyroid cancer cells would be 
generated from transformation of cell compartment at different stages of 
differentiation, TSCs, thyroblasts and prothyrocytes, which would result in ATC, PTC 
and FTC, respectively. This observation mostly reflects the need to identify the cells-
of-origin and tumor-related driven mutations in order to explain the transition from 
non-malignant hyper-proliferative lesion to well established thyroid cancers and 
translate the identified alterations into new therapies. Thus, the aim of this work was 
to demonstrate that the thyroid tumor histotypes derive from distinct genetic 
alterations occurring within the same target cells, that are TCSs, or from distinct cells-
of-origin, at diverse differentiation stages, able to acquire the first driven-mutation 
having the ability to initiate the tumor (Fig. 1A and 1B). With a view to differentiate 
in vitro hESCs into thyroid-like cells at different stages of differentiation, we tested 
various experimental approaches, among which we decided to use the most reliable 
protocol to recapitulate the key signaling pathways occurring during in vivo human 
thyroid development (Fig 3A, 3B and 3C). The implication of Nodal and Wnt 
signaling pathways in vertebrate definitive endoderm (DE) differentiation is well 
described. Activin A and Wnt activators in combination with Noggin, a BMP 
antagonist, are commonly used to direct the mesendoderm towards anterior foregut 
endoderm derivatives such as thyroid gland (32, 36-38). Monolayer of hESCs seeded 
in matrigel and treated with Activin A and low serum produced cultures consisting of 
up to 80% definitive endoderm cells in 5 days as shown by Foxa2, SOX-17, c-Kit and 
CXCR-4 endodermal markers expression (Fig. 3A, 3D, 3E, 3F and 3G). In order to 
direct DE towards the thyroid competent DE positive for SOX-2 and Foxa2 anterior 
foregut endodermal markers, day 5 hESC-derived endoderm cells were exposed for 
24 hours to BMP and activin/TGF-β signalling inhibitors (Noggin and SB431542, 
respectively) (Fig. 3A, 3F and 3G). Stage-specific inhibition of BMP and TGF-β 
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 signaling renders these endodermal progenitors competent to specify efficiently into 
endodermal thyroid progenitors expressing TTF-1 (Fig. 3A, 3F and 3G). Induction of 
BMP and FGF signaling by exposing these cells, until day 22, to specific factors 
including BMP-4, Wnt3a, FGF-10, FGF-7, EGF, FGF2, FGF10 and heparin 
(WFKBEF2-F10), resulted in the specification of thyroid competent DE into thyroid 
progenitor cells expressing specific thyroid markers such as TTF-1, Pax-8, Tg, TPO, 
TSH-R and NIS (Fig. 3A, 3F and 3G). At this stage, TTF-1 and Pax-8 co-expression 
is an essential prerequisite to verify that endoderm cells of thyroid lineage has been 
derived. In order to obtain the full maturation into Day 25 thyroid-like cells, day 22 
thyroid progenitors were exposed for 3 days to a maturation media supplemented with 
TSH, IGF-1 and NaI resulting in up-regulation of specific thyroid differentiation 
markers (Fig. 3A, 3F and 3G). Day 25 thyroid-like cells in response to a prolonged 
TSH treatment have the capacity to organize into thyroid-specific three-dimensional 
structures, the follicles expressing thyroid differentiation markers such as TP0, NIS 
and Tg (Day 32) (Fig. 3C). 
These data argue that the choice to use hESCs could represent a reliable and 
innovative strategy to reproduce the cellular hierarchy of normal thyroid tissue in a 
vitro experimental setting,  breaching toward the cell-of-origin identification. 
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Figure 3. Inhibition of BMP and TGFβ signaling pathways promotes hESC-derived endoderm
differentiation into thyroid-like cells. (A) Schematic representation of culture protocol for in vitro
hESCs differentiation into endodermal TTF-1+ cells with thyroid lineage fate. (B) Representative phase
contrast analysis of hESCs cultures at different differentiation stages (Day 0, hESCs; Day 6, Competent
DE; Day 22, thyreoblasts; Day 25 prothyrocytes); (C) Immunofluorescence analysis of cytocheratin 19
(CK19), NIS, TSH-R, TPO and Tg in follicle (Day 32) with relative H&E staining on paraffin embedded
sections. (D and E) Representative flow cytometry profiles of Oct-3/4, SOX-2 and Nanog pluripotent
markers, c-Kit, CXCR-4, SOX-17 and Foxa2 definitive endodermal markers, TTF-1 and Pax-8 thyroid
markers on hESCs (Day 0) and DE (Day 5), respectively. The grey histograms represent the isotype-
matched controls. (F) Percentage of Oct-3/4, SOX-2, Nanog, SOX-17, Foxa2, TTF-1, Pax-8, Tg, TPO,
TSH-R and NIS positive cells on Day 0 (control), Day 5, Day 6, Day 22 and Day 25 evaluated by
immunofluorescent. (G) hESCs-derived cultures on Day 0 (control), Day 5, Day 6, Day 22 and Day 25,
immunostained for Oct-3/4, SOX-2, SOX-17, Foxa2, Tg and NIS proteins..
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 2.3.3 microRNAs as regulators of thyroid cell specification  
The growing body of experimental evidence has shown that microRNAs play an 
important role in maintenance and differentiation of stem cells fate (39-44). miRNA 
expression profiles are highly variable during embryonic development and in 
adulthood (45). Increasly evidences demonstrated that an intact microRNAs 
processing machinery is an essential prerequisite for proper function of several organs 
including thyroid gland (46-48). Although it is well established that microRNAs 
finely modulate the expression of thyroid specific genes involved in maintenance of 
tissue homeostasis, the role of these short-non-coding RNAs in normal thyroid 
development is still poorly clarified. In order to enrich the knowledge regarding the  
in vitro differentiation of hESCs into thyroid cells, it would be helpful thoroughly 
clarify the regulatory mechanisms that contribute to thyroid cell specification. 
Therefore, we investigated the differentially expressed microRNAs during in vitro 
hESCs differentiation into thyroid cell lineage to elucidate their potential role in 
normal thyroid tissue development. 
We compared microRNA expression profiles among hESCs at diverse differentiation 
stages and we found that miR-375, known to be highly expressed in hESCs-derived 
definitive endoderm (49), is up-regulated in definitive endoderm and especially in 
competent definitive endoderm than in hESCs, and its expression level declined later 
during the differentiation process (Fig. 4A). miR-375 acts regulating target genes, 
including the endodermal marker SOX-17, involved in development of endodermally 
derived organs such as thyroid gland (49). Likewise, some of the miR-302 family 
members, essential for maintenance and renewal of the hESCs (40-41), is up-
regulated in hESCs and its expression levels resulted down-regulated during cell 
lineage specification (Fig. 4A). Furthermore, we showed that the expression of miR-
143, miR-145 and some of the let-7 family members was low in hESCs but highly up-
regulated during in vitro differentiation of DE into thyroid cells (Fig. 4A). Our data 
are strongly supported by recent finding claiming that let-7 family plays an important 
role in regulating cell proliferation and differentiation during development and 
furthermore, that the expression levels of miR-143 and miR-145 are highly up-
regulated during cell specification (50-52). It is well known that pluripotency genes 
Oct-3/4 and SOX-2 are direct targets of miR-145 and that over-expression of the same 
microRNA results in inhibition of its pluripotency targets inducing lineage 
differentiation (50-51). Several investigators reported altered miR-145 expression 
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 levels in ATC cell lines (50). According to these evidences, we observed that the 
expression levels of miR-145 are significantly down-regulated in CSCs from ATC 
specimens as compared with CSCs from well differentiated thyroid carcinoma FTC, 
hESCs-derived TSCs and hESCs-derived thyroid-like cells (Fig. 4B). Given the low 
expression levels of miR-145 in CSCs from ATC specimens, characterized by a 
down-regulation of thyroid differentiation markers such as NIS, Pax-8 and Tg (2-3, 7, 
51), it could be hypothesized that miR-145 may modulate differentiation of thyroid 
follicular cells. Indeed, research findings demonstrated that inhibition of miR-145 in 
primary cultures of normal thyroid tissue samples results in down-regulation of 
specific thyroid differentiation markers (51).  
According to our preliminary data we could speculate that an undamaged microRNAs 
processing machinery is an essential prerequisite for maintenance and differentiation 
in vitro of hESCs towards a TFC fate. These results suggest that microRNAs play an 
important role in proper development and function of thyroid gland supporting the 
well known concept that deregulation of specific microRNAs are involved in human 
thyroid diseases. 
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Figure 4. microRNAs regulate normal development and function of thyroid gland. (A)
Correlation plot of up- and down-regulated microRNAs in Day 0 hESCs, Day 5 DE, Day 6
Competent DE; Day 22 thyreoblasts and Day 25 prothyrocytes using equivalent Cт values where the
original Cт values are projected to 100% target efficiency. (B) Basal expression levels of miR-145 in
hESC-derived TSCs (day 6), hESC-derived thyroid-like cells (Day 25) and CSCs isolated from ATC,
PTC and FTC specimens.
B
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 2.4 Future perspectives and conclusions 
Since the miR-145 role in pluripotency maintenance and cellular differentiation, it has 
been proposed to be a tumor suppressor in several tumors. Research findings showed 
that undifferentiated thyroid carcinomas are characterized by loss of specific thyroid 
follicular cell markers expression resulting in a decrease of adjuvant therapies 
efficacy. Given our preliminary data regarding the loss of miR-145 expression in 
CSCs from ATC specimens, it could be hyphotized that miR-145 may modulate 
differentiation of thyroid follicular cells. In our previously published work we 
demonstrated that in accordance with its undifferentiated phenotype, CSCs isolated 
from ATC specimens did not express Tg, whereas CSCs isolated from PTC and FTC 
specimens showed a diffuse expression (24). In order to clarify the potential role of 
miR-145 in thyroid carcinogenesis, we will investigate the association between miR-
145 expression levels and specific thyroid differentiation markers in CSCs isolated 
from ATC, PTC and FTC specimens. 
Recent advantages in genome editing have enabled to efficiently modify endogenous 
genes in a wide variety of cells. CRISPR (clustered regularly interspaced short 
palindromic repeats)/Cas9 technology represents a significant improvement over other 
next-generation genome editing tools, reaching a new level of targeting, efficiency, 
and ease of use. The CRISPR/Cas9 system allows for site-specific genomic targeting 
in virtually any organism. Our intent was to prove that the different thyroid tumor 
histotypes were determined by different genetic alterations occurring within the same 
target cell or inside distinct cells-of-origin constituting the thyroid tissue. To address 
this point, we will transfect TSC compartment with CRISPR Cas9 bearing 
TP53R248Q alone and in combination with BRAFV600E, RET/PTC1 or 
NRASQ61R, thyroblasts with CRISPR Cas9 bearing BRAFV600E or RET/PTC1, 
and prothyrocytes with CRISPR Cas9 bearing NRASQ61R (6). 
We will investigate whether self-renewal capacity is directly correlated with the above 
mentioned genetic alterations common in thyroid tumor histotypes. Moreover, cells 
bearing these genetic alterations will be orthotopically injected into the thyroid mice 
gland. Furthermore, target cells over-expressing the above mentioned oncogenes and 
their matched xenografts will be analyzed for post-translational modifications analysis 
of the proteins commonly related to the metastatic and tumorigenic signaling 
pathways. Moreover, such knowledge could potentially lead to the creation of animal 
models useful to understand the strengths and limitations of new individualized 
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 treatment regiments. According to the well known concept that SCs and CSCs share 
the ability to self-renew, it is reasonable to propose that cancer cells use the self-
renewal machinery normally exploited in stem cells. It has been already established 
that many pathways classically associated to cancer progression may also regulate the 
SCs maintenance, and also that the events underlining the tumor transformation 
followed by tumor suppressor gene loss or oncogene activation can occur both in 
long-lived somatic stem cells and in short-lived differentiated cells. These findings 
together with our preliminary observations could define a good model to identify the 
cells-of-origin and tumor-related driven mutations designing a gateway to clarify the 
molecular basis of malignant thyroid transformation. 
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Recent discoveries highlight the emerging role of estrogens in the initiation and progres-
sion of different malignancies through their interaction with stem cell (SC) compartment.
Estrogens play a relevant role especially for those tumors bearing a gender disparity in
incidence and aggressiveness, as occurs for most thyroid diseases. Although several exper-
imental lines suggest that estrogens promote thyroid cell proliferation and invasion, their
precise contribution in SC compartment still remains unclear. This review underlines the
interplay between hormones and thyroid function, which could help to complete the puzzle
of gender discrepancy in thyroid malignancies. Defining the association between estrogen
receptors’ status and signaling pathways by which estrogens exert their effects on thyroid
cells is a potential tool that provides important insights in pathogenetic mechanisms of
thyroid tumors.
Keywords: thyroid cancer, stem cells, cancer stem cells, estrogens, thyroid hormones, growth factors
INTRODUCTION
The endocrine system consists of a network of glands secret-
ing hormones, which are chemical messengers that cooperate in
growth, development, metabolism, and reproductive functions.
The largest endocrine organ in the human body is the thy-
roid gland, whose function is the systemic metabolic regulation
through thyroid hormones (THs) produced by follicular cells, and
calcitonin produced by parafollicular cells. Different malignancy
histotypes can arise from these cells: papillary (PTC), follicu-
lar (FTC), and anaplastic thyroid carcinomas (ATC) originate
from follicular cells, while medullary thyroid carcinomas (MTC)
derive from parafollicular cells (1). Notably, more than 95% of
thyroid carcinomas (TCs) arise from follicular cells. These malig-
nancies are indolent tumors treated by surgical resection with
or without radioactive-iodine ablation since they maintain their
distinct potential to concentrate Iodine. The loss of typical thy-
roid cell characteristics and functions, including expression of
the thyroid-stimulating hormone (TSH) receptor (TSH-R), thy-
roglobulin (Tg), thyroid peroxidase (TPO), and sodium iodide
symporter (NIS), defines the hallmark of ATCs, which are lethal
malignancies with no effective therapy (1–3).
Besides genetic alterations in mitogen-activated protein kinase
(MAPK), PI-3 kinase (PI3K), and TSH signaling pathways, thy-
roid carcinogenesis is fostered by the microenvironment, growth
factors (GFs), and various hormones, including estrogens (4).
Hormones can set off a cascade of signaling pathways, enhanc-
ing or contrasting specific effects triggered by other factors. Based
on this scenario, the role of estrogens has been proposed in the
pathogenesis of thyroid proliferative and neoplastic disorders.
This hypothesis is supported by data regarding gender incidence,
which reported a frequency of thyroid nodules about three to
four times higher in women than in men with a peak rate occur-
ring earlier in women (5, 6). Furthermore, the clarification of the
estrogen-driven pathogenesis could be crucial in explaining why
PTC constitutes the seventh most common cancer in the female
gender (7, 8). An in vivo study reported that circulating estrogens
are directly responsible for the increased female susceptibility to
thyroid disease, through PI3K pathway activation and repressing
p27 expression. The authors also observed a significant estrogen
role in the transcriptional regulation of TPO, DUOX1, and NIS
genes (9). Although several studies have demonstrated a direct
action by estrogens on thyroid growth and function (7, 10–12),
the precise mechanism underlying the proliferative and neoplas-
tic disorders still remains undefined. In particular, it would be
interesting to explore the role of hormones in TC initiation.
The cellular origin of TCs has been explained by different
models (Figure 1). The multistep carcinogenesis model predicts
that TC originates from follicular cells as a consequence of mul-
tiple mutations accumulated throughout their life-span. These
events are characterized by a dedifferentiation process with a
marked epithelial-to-mesenchymal transition (EMT), in which
well-differentiated TC cells transform into a more undifferentiated
phenotype (1). The fetal cell carcinogenesis model hypothesizes
that TC cells would be generated by transforming three types of
fetal thyroid cells, stem cells (SCs), thyroblasts, and prothyrocytes,
which result in ATC, PTC, and FTC, respectively (13, 14). The
heterogeneity of tumor bulk had led to a cancer stem cells (CSCs)
model to propose TC as an SC disease. The growing body of exper-
imental evidence has revealed that an accumulation of genetic
abnormalities in tissue-resident SCs or in their more commit-
ted progenies, concomitant with the niche epigenetic alterations,
result in their malignant transformation (15, 16).
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FIGURE 1 |The cellular origin of thyroid carcinomas is shown. According
to the multistep carcinogenesis model, TC originates from follicular cells as a
consequence of multiple mutations accumulated throughout their life-span.
Thyrocytes could give rise to PTC by RAS and BRAF mutations or RET/PTC
and NTRK1 rearrangements and to FTC by point mutations of the RAS gene
and PAX8/PPARγ rearrangement. ATC derive from PTC and FTC after
deregulation of the p53 and the Wnt/β-catenin pathway. In fetal cell
carcinogenesis model, three types of fetal thyroid cells were proposed to
generate different forms of thyroid cancer. Fetal thyroid stem cells,
characterized by expression of the oncofetal fibronectin (OF), generate ATC,
thyroblasts, which express OF and the differentiation marker Tg, are proposed
to be the cellular origin of PTC. The more differentiated prothyrocytes,
expressing Tg, give rise to FTC. The cancer stem cells model proposes TC as
an SC disease. The accumulation of mutations in differentiated thyrocytes
leads to their transformation. A subset of these cells may (in more aggressive
tumor types) dedifferentiate and assume CSC characteristics.
The“cell-of-origin”concept explains how a normal cell acquires
the first alteration able to trigger tumor initiation (tumor-
initiating cells, TICs) (17). Wnt pathway plays a crucial role in
SC/progenitor compartment maintenance, and has been described
in several tumors, including TC, resulting in nuclear β-catenin-
induced proliferation (18–20).
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In this review, the most current findings supporting the car-
cinogenesis effects of estrogens and THs will be addressed. A
special emphasis will be given to the role of exogenous and
endogenous GFs affecting thyroid proliferative pathways in SC
compartment.
ESTROGENS
As recently published by Morrison’s research group, estrogens are
involved in increasing hematopoietic SC self-renewal in female
subjects and more specifically during pregnancy (21). It is likely
that normal and tumor thyroid tissues, which express estro-
gen receptors (ER), could be subject to the same mechanism of
estrogen action (10, 22–24).
Involved in cellular processes such as growth, cell motility,
and apoptosis, in reproductive tissues and other organs, including
endocrine glands, estrogens are mainly produced by the adrenal
cortex and ovary, but also by the thyroid (25, 26). They are present
in women and men with a notable increase in women at reproduc-
tive age. The three principal estrogens, estrone (E1), estradiol (E2),
and estriol (E3), are processed in metabolites with different estro-
genic abilities, which create a different risk in developing cancer
(27–29).
Estradiol is the most potent estrogen since it has the high-
est affinity to its receptors. Estrogens perform their function by
binding to ER alpha and beta (ER-α, ER-β), and a transmem-
brane intracellular non-classical ER G-protein-coupled receptor
30 (GPR30) (Figure 2). ER-α and ER-β are soluble intracellular
nuclear receptors, belonging to a ligand-dependent nuclear recep-
tor superfamily of transcription factors (TFs) (25, 26). ER-α is
the key factor of E2-induced proliferation with an anti-apoptosis
effect. In females of reproductive age, ER-α levels are higher in PTC
compared to nodular goiter patients, showing a positive correla-
tion between ER-α and Ki-67 expression levels. In contrast, ER-β
is associated with apoptosis and growth inhibition, providing a
negative correlation with mutant P53 (30). PPARγ also interacts
with ER-α inhibiting each other, and with ER-β enhancing their
inhibitory effect on cell proliferation and migration (31). In light
of this, the ER-α/ER-β ratio could be helpful to elucidate the TC
pathophysiology (25, 32).
The interaction between estrogens and ERs signals through
different pathways:
• Genomic (or classical) estrogen-signaling: after accessing the
cell through passive diffusion, E2 binds to ER, which changes
its conformation and homo- or heterodimerizes (E2–ER). This
complex translocates into the nucleus, where it binds to the 15-
bp palindromic estrogen response element (ERE) located in the
regulatory regions of target genes. This interaction leads to a co-
activators recruitment, which in turn allows expression of genes
involved in proliferation (33, 34).
• Estrogen response element-independent genomic actions (TFs
cross-talk): ERE-lacking genes can be activated by modulating
other TFs through protein–protein interactions. This molecular
mechanism induces chromatin remodeling, histone unwinding,
and interaction with the basal transcription machinery complex
(35–37).
• Non-genomic (or membrane-initiated) estrogen-signaling: E2
activation of plasma membrane-associated ER and GPR30 pro-
motes the MAPK and PI3K signaling pathways and/or increases
the Ca2+ levels (10, 38–40). They can also activate G-proteins
resulting in cAMP production, similar to TSH signaling in thy-
rocytes, and assist the activation of metalloproteinases (MMPs)
and the GF pathway (5).
• Ligand-independent signaling: in absence of E2, GFs can stim-
ulate ERs directly or indirectly through MAPK and/or PI3K
pathways (41).
The cross-talk between genomic and non-genomic path-
ways, as well as the integrative signaling by E2 in different cell
compartments, leads to a synergy that provides plasticity in
cell response. Estrogens dispatch their proliferative role also by
increasing T3 levels and stimulating the iodine-uptake and TPO
activity (42).
Furlanetto et al. (43) reported that E2 increases prolifera-
tion of thyroid cells down-regulating NIS. These data underline
the pivotal role of estrogens in the SC compartment mainte-
nance. In normal and tumor thyroid cell lines, Rajoria et al.
documented that E2 is associated with increased proliferation,
adhesion, invasion, and migration via β-catenin (7) and MMP-9
modulation (44). Likewise, E-cadherin down-regulation and β-
catenin translocation sustain the metastatic activity of TC cells
(24). These results confirmed the findings by Kouzmenko et al.,
which reported the first evidence of cross-talk between estrogens
and Wnt pathways through functional interaction of β-catenin
with ER-α (45).
Xu et al. (8) analyzed whether differentiated and SC/progenitors
could be target of estrogen action in thyroid. SCs isolated from goi-
ter tissue enhanced their sphere-forming ability in presence of E2.
Moreover, thyroid-sphere cells showed ER-α mRNA levels eight
times higher than those of more differentiated thyrocytes. This
suggests the gender discrepancy in TC incidence and a difference
in terms of aggressiveness and survival.
THYROID HORMONES
Thyroid hormones control the secretion of thyrotropin-releasing
hormone (TRH) from the hypothalamus and TSH from the
anterior pituitary through negative feedback loops (1). Thyroid
homeostasis and function are regulated by a concert of signals
accumulated from TSH and GF pathways. TSH binds to TSH-
R and induces the coupling of different G-proteins, stimulating
adenylate cyclase (AC) and phospholipase C (PLC) (Figure 2).
This promotes iodide uptake and TG, TPO, and NIS expression,
producing thyroxine (T4) and triiodothyronine (T3) (19, 46). On
the contrary, intracellular Ca2+ and PLC regulate iodine release,
H2O2 production, and Tg iodination (47, 48). Although cAMP is
the main mediator of TSH stimulation in thyroid cell growth, TSH
via PI3K increases cyclin E levels leading to cell cycle progression
(49, 50). TSH-R is also associated to the MAPK pathway through
its desensitization and internalization apparatus (51).
Gain-of-function mutations in TSH-R or Gs genes result in
increased cAMP accumulation and TSH-independent prolifera-
tion, which account for hyperfunctioning nodules in patients with
multinodular goiters (52, 53). These alterations result insufficient
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FIGURE 2 | Signaling pathways in follicular cells are shown. The main
regulators of thyroid proliferation and function act through TSH signaling and
GF pathway. THs control the secretion of TSH, which binds to TSH-R and
induces the coupling of G-proteins stimulating AC and PLC. TSH also acts via
PI3K pathway. GFs act via MAPK and PI3K pathways regulating the
expression of genes involved in survival, cell cycle progression, and
proliferation. Estrogens regulate proliferation, cell motility, differentiation, and
apoptosis through four different mechanisms: (1) genomic (or classical)
estrogen-signaling: E2–ER complex translocates into the nucleus, where it
binds to ERE-sequences; (2) ERE-independent genomic actions (TFs
cross-talk): genes lacking in ERE-sequences are activated by other TFs in the
nucleus through protein–protein interactions; (3) non-genomic (or
membrane-initiated) estrogen-signaling: E2 activation of plasma
membrane-associated ER and GPR30 trigger the activation of MAPK and PI3K
pathways and/or increases the Ca2+ levels; (4) ligand-independent signaling: in
absence of E2, GFs can stimulate ERs directly or indirectly through MAPK
and/or PI3K pathways. THs play a critical role in development and
homeostasis. Nuclear TRs activate gene expression by binding to RXR, which
in turn bind to TRE-sequences. Given that EREs share a similar nucleotide
sequence with TREs, ERs and TRs can interact and regulate several
transcriptional responses. The cross-talk between genomic and non-genomic
pathways and other integrative signaling lead to a synergic cell response.
for the malignant transformation of thyroid cells (54, 55). Hence,
it is likely that other factors intervene in the SC compartment,
which is assumed to be the target of neoplastic transformation.
Alterations of the Wnt pathway effectors are involved in cancer
initiation and progression (56). In particular, TSH-mediated Wnt-
1 over-expression and GSK-3β inhibition promote thyroid cell
proliferation (57, 58).
Thyroid hormones play a critical role in the tissue development
and homeostasis by direct transcriptional regulation or modula-
tion of different pathways (59). Although T4 is the predominant
hormone produced by the thyroid, T3 is the active form that
mediates gene regulation binding with a higher affinity to thy-
roid receptors (TRs) (60). Nuclear TRs activate gene expression by
binding with the retinoid X receptors (RXRs) to TH response ele-
ments (TRE), located on the promoters of target genes (Figure 2)
(61). Given that EREs share a similar nucleotide sequence with
TREs, ERs and TRs can interact and regulate several transcrip-
tional responses to environmental stimuli (5). Interestingly, ERE
can act as a peroxisome proliferator responsive elements (PPRE),
binding PPARγ/RXR. It can henceforth inhibit ER transactivation
through a competition for ERE binding (62). In line with this
cross-interaction, the proliferative effect of estrogens on human
NPA-87-1 PTC cell line is TSH-independent (63). Lima et al.
demonstrated a more direct proliferative effect since E2 admin-
istration to prepubertal and adult rats enhances thyroid weight
without significant changes in T3, T4, and TSH hematopoietic
levels (42).
Recent studies in human cancers and mouse models pro-
vide strong evidence that the loss of TRs function contributes
to cancer initiation and progression (64). While the TRα1 trigger
directly promotes transcription of CTNNB1 (65, 66), the effect
generated by the TRα2 stimulation in SC compartment is still
unknown. Cross-talk between THs-TRα1 and Wnt pathway has
been confirmed by the up-regulation of several SC markers (67).
Furthermore, it was reported that aberrant nuclear localization of
β-catenin-induced by CTNNB1 mutations contributes to the pro-
gression of ATCs (68). Data reported by Todaro et al. showed that
E-cadherin down-regulation together with β-catenin activation
confers an invasive capacity and higher metastatic rate to thyroid
CSCs (18).
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GROWTH FACTORS
In thyroid, GFs exert their proliferative effects by inducing the RTK
dimerization that activates the downstream PI3K pathway and the
MAPK cascade via G-proteins (Figure 2). Alterations in genes
involved in the MAPK pathway led to its constitutive activation,
which represents a typical feature of TC (1). In particular, muta-
tions in RET and NTRK and alterations in RAS and BRAF intracel-
lular signal-transducers are clearly implicated in PTC pathogenesis
(69). RAS point mutations and PAX8/PPARγ rearrangement have
been frequently implicated in FTC pathogenesis (70, 71). The inac-
tivation of RASAL1 (encoding a RAS GTPase-activating protein)
by hypermethylation and mutations provides a new genetic back-
ground for FTCs and ATCs (72). Besides nuclear β-catenin accu-
mulation and p53 inactivation, oncogenic activation of MAPK
and PI3K/Akt/Foxo3a are frequently found in ATCs (2, 73, 74).
The acquisition of a TERT promoter mutation was recently asso-
ciated with clinical–pathological aggressiveness in FTCs and BRAF
mutation-positive PTCs (72, 75).
The mesenchymal tissue is involved in thyroid development
being that it releases Pro-epidermal growth factor (EGF) and basic
fibroblast growth factor-2 (FGF-2), promoting cell proliferation
and repressing differentiation (76, 77). Estrogens play a pivotal
role in this context by inducing the production of EGF and other
TFs, such as TGF-α (5).
After EGF binding, RTKs of the ErbB family (EGFR/ErbB1,
ErbB2, ErbB3, and ErbB4) achieve activation through the arrange-
ment in homo- and/or heterodimeric complexes (78, 79). In thy-
roid, TSH increases the expression of EGFRs that in turn promote
the EGF mitogenic effect and contribute to gland homeostasis. The
combination of specific EGFRs regulates the stimulation inten-
sity, inducing transformation. Indeed, an increased expression of
EGFRs in TCs compared to normal tissue has been reported (80).
EGFR/ErbB1 over-expression and its constitutive phosphoryla-
tion have been observed on ATC samples and cell lines (81). Their
expression has been retrieved in 90% of the PTC samples exam-
ined by Song (82). In combination with the repression of VEGF,
EGF inhibitors could be a promising therapy for ATCs as demon-
strated by in vitro studies (83, 84). EGF is also supplemented in
the serum-free culture medium, which is used to isolate SCs and
CSCs in vitro (18, 85–90).
Similarly, the cell response to FGF is regulated by FGF RTKs
(FGFRs 1–4). FGF-2 exerts autocrine and paracrine stimulatory
effects on thyroid growth, since the basement membrane of thy-
rocytes is able to produce FGF itself. FGF is also used in vitro for
the maintenance of SC niche (18, 91); in particular, it could have
an inhibitory effect on thyroid function through cAMP inhibition
and TSH’s activity weakening (79). In TC, increased FGF-2 levels
and FGFR2 over-expression are critical in tumor progression and
neovascularization (92, 93). Therefore, the differential expression
in normal and malignant conditions could make this receptor a
potential diagnostic marker for TCs (94).
Growth factors also affect development and metabolic
processes through insulin-like growth factor (IGF). After bind-
ing of their ligands, IGF receptors (IGF-Rs) autophosphorylate
their intracellular domain and activate the MAPK and PI3K cas-
cade (95). Consistently, IGF enhances the TSH mitogenic effect
on follicular cells (96); on the other hand, it also cooperates with
FGF-2 in establishing and maintaining the SC niche in vitro (96).
Indeed, IGF pathway effectors are over-expressed in CSCs: IGFR2
is involved in an autocrine loop that sustains SC renewal, and IGF
increases the expression of Oct-4 and Nanog when added to the
culture medium (87, 97, 98).
ESTROGEN-GROWTH FACTORS INTERACTING PROTEINS
Recently, there has been a focus on importance of the ER-GFs
interacting proteins on cancer cell proliferation and invasivity.
An example is mediator of ERbB2-driven cell motility (MEMO),
which enhances ER-α extra-nuclear functions through the inter-
action with IGFR1 and ERbB2, activating MAPK and PI3K
signaling (99).
CONCLUDING REMARKS
Since the theory of fetal carcinogenesis has initially been pos-
tulated, thyroid CSCs have been studied for their potential role
as TICs. It has been hypothesized that various factors could be
involved in the malignant transformation, such as aberrant mole-
cular events converging to RTK, MAPK, and PI3K pathway activa-
tion. Besides the oncogenes contribution, it is likely that a network
of various hormones and GFs could maintain the SC niche and
enhance the proliferation of progenitors sustaining tumor bulk
growth. Indeed, recent studies demonstrate that sexual hormones
could exert a supportive role in the propagation of SCs and prog-
enitors, as suggested by the cross-talk between estrogen-signaling
and Wnt pathway. Furthermore, the latter pathway has also been
observed interacting with THs in SC compartment and so acceler-
ating tumorigenic processes. This mechanism could be benefited
by the interaction between different cascades, which enhances or
contrasts specific cellular response in tumor conditions. In conclu-
sion, an in-depth study on the concert between estrogens, THs, and
GFs could be helpful to elucidate hormones-driven thyroid car-
cinogenesis. Gaining more insight into this interaction could also
explain the gender imbalance in tumor incidence for the purpose
of identifying a more targeted approach in TC therapy.
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Breast cancer stem cells rely on fermentative
glycolysis and are sensitive to 2-deoxyglucose
treatment
D Ciavardelli*,1,2, C Rossi2,3, D Barcaroli2,3, S Volpe4, A Consalvo2,3, M Zucchelli2,3, A De Cola2,3, E Scavo4, R Carollo4,
D D’Agostino2,3, F Forlı`2,3, S D’Aguanno5, M Todaro4, G Stassi4, C Di Ilio3, V De Laurenzi*,2,3,7 and A Urbani5,6,7
A number of studies suggest that cancer stem cells are essential for tumour growth, and failure to target these cells can result in
tumour relapse. As this population of cells has been shown to be resistant to radiation and chemotherapy, it is essential to
understand their biology and identify new therapeutic approaches. Targeting cancer metabolism is a potential alternative
strategy to counteract tumour growth and recurrence. Here we applied a proteomic and targeted metabolomic analysis in order
to point out the main metabolic differences between breast cancer cells grown as spheres and thus enriched in cancer stem cells
were compared with the same cells grown in adherent differentiating conditions. This integrated approach allowed us to identify
a metabolic phenotype associated with the stem-like condition and shows that breast cancer stem cells (BCSCs) shift from
mitochondrial oxidative phosphorylation towards fermentative glycolysis. Functional validation of proteomic and metabolic data
provide evidences for increased activities of key enzymes of anaerobic glucose fate such as pyruvate kinase M2 isoform, lactate
dehydrogenase and glucose 6-phopshate dehydrogenase in cancer stem cells as well as different redox status. Moreover, we
show that treatment with 2-deoxyglucose, a well known inhibitor of glycolysis, inhibits BCSC proliferation when used alone and
shows a synergic effect when used in combination with doxorubicin. In conclusion, we suggest that inhibition of glycolysis may
be a potentially effective strategy to target BCSCs.
Cell Death and Disease (2014) 5, e1336; doi:10.1038/cddis.2014.285; published online 17 July 2014
One of the main problems in the therapy of breast tumour is
long-term relapse. This can in part be explained by failure to
eradicate a subset of cells within the tumour that are then
capable of sustaining tumour growth. These cells share a
number of features with stem cells and have therefore been
called cancer stem cells (CSCs). CSCs have been isolated
from a variety of solid tumours, including breast cancer1 and
appear to have role in resistance to treatment as well as in
metastasis formation.2 Indeed, CSCs present several intrinsic
mechanisms of resistance to conventional antitumour drugs
and radiation therapy such the overexpression of adenosine
triphosphate (ATP)-binding cassette (ABC) drug transporters,
activation of survival pathways, increased production of anti-
apoptotic factors, higher defences against oxidative stress,
and efficient repair of DNA damage.3 Therefore the
development and validation of new therapeutic strategies
targeting CSCs is urgently needed to improve clinical
outcome.
Recently, the interest on studying cancer metabolism and
the so called Warburg effect has grown as targeting specific
metabolic pathways might be a promising approach to cancer
therapy.4,5 Warburg effect defines cancer dependence on
fermentative glycolysis allowing for the diversion of key
metabolites into cellular biosynthetic pathways in proliferating
cancer cells,6 including CSC, and it has been suggested that it
can be exploited to develop new pharmacological treatments
that can counteract the chemo-resistance of these cells.7,8
It has also been suggested that metabolic changes may
have a causal role in inducing different phenotypic states of
cancer cells. As an example, Dong et al.9 have shown that
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silencing of the gluconeogenic enzyme fructose-1,6-bipho-
sphatase that activates fermentative glycolysis results
in a stem-like phenotype. Despite their importance, the
metabolic features of CSCs still remains largely unknown.
Recently, it has been shown that CSCs isolated from several
solid tumours display significant alteration of energy metabo-
lism and are more glycolytic compared with more differen-
tiated tumour cells10–13or normal stem cells.14 However, this
is still a controversial issue as previous studies have shown
that CSCs are less glycolytic than the differentiated ones.15
Here, using an integrated proteomic and targeted meta-
bolomic approach, we show that the metabolism of breast
cancer stem cells (BCSCs) grown as spheres is strongly
linked to fermentative glycolysis comparedwith the same cells
grown in adherent differentiating conditions (spheroid-derived
adherent cells (SDACs)). On the basis of these evidences, we
sought to test the effect of a well-characterized glycolytic
inhibitor, 2-deoxy-D-glucose (2-DG),16,17 alone or in combi-
nation with the widely used chemotherapeutic doxorubicin
(Doxo) on BCSCs’ growth and proliferation. Our results
indicate that BCSCs are highly sensitive to 2-DG that also
shows a synergic effect with Doxo treatment.
Results
Differential proteomics analysis indicates a shift toward
fermentative glucose metabolism in BCSC spheres. In
this study, we have analysed differential protein expression
profiles of BCSCs and SDACs. As previously reported,18 the
in vitro model adopted for differentiated cells, conventionally
reported as SDACs, relies on sphere cells cultured in
Dulbecco’s modified Eagle medium (DMEM) supplemented
with 10% fetal bovine serum (FBS) in adherent conditions.
These cells express higher levels of cluster of differentiation
24 (CD24) as expected for SDACs (Supplementary
Figure S1).19,20
Compared with the gel electrophoresis-mass spectrometry
(GC–MS) proteomics approach, label-free liquid chromato-
graphy tandem mass spectrometry (LC-MS/MS) provides a
high throughput and low expensive analytical method for
characterization of complex protein mixtures with suitable
sensitivity and repeatability. Protein identification, quantifica-
tion, and data quality of exact mass retention time clusters
(EMRTs), which are the recorded mass species associated to
their exact masses and retention times, were evaluated.
A total of 39 379 and 39 379 EMRTs were determined for the
comparison of BCSCs grown as spheres versus SDACs for
3.5 and 7 days, respectively. For each replicate conditions,
the distribution of mass error was under 15 p.p.m. (Figures 1a,
d and g for BCSCs and SDAC collected after 3.5 days and
7 days, respectively), the intensity coefficient of variation
expressed as percentage (% CV intensity) had a Gaussian
distribution with all values o4.5% (Figures 1b, e and h for
BCSCs and SDAC collected after 3.5 days and 7 days,
respectively) and the retention time coefficient of variation
expressed as percentage (% CV RT) waso10% (Figures 1c,
f and i for BCSCs, SDAC collected after 3.5 days and 7 days,
respectively) with most of the species o5%. Applying
the stringent criteria of protein identification and
quantification described in the Materials and Methods, we
identified 54 and 28 proteins differentially expressed in
BCSCs compared with SDACs collected after 3.5 and 7 days
in differentiating conditions. The lists of differential
proteins are shown in Supplementary Tables S1 and S2,
while the details of peptide identifications are reported in
Supplementary Tables S3 and S4.
Venn analysis (Figure 1j) shows that 19 proteins were
upregulated in spheres as compared with both time points of
differentiation, whereas 5 were downregulated in the same
experimental conditions. Interestingly, the expression levels
of these proteins did not change between 3.5 and 7 days in
adherent conditions (Figure 1k), thus suggesting that the
differences were strictly related to the stem-like condition. We
therefore decided to use SDACs collected after 3.5 days in
adherent conditions for all the subsequent studies, thereby
focusing on early changes between the BCSC and SDAC
condition.
Bioinformatic analysis of these differentially expressed
proteins identified two significant overlapping protein networks
related to the haematological, immunological, and infla-
mmatory diseases (score¼ 62) and the free radical scaven-
ging and cancer pathway (score¼ 3) (Figures 2a and b).
Functional analysis based on GO terms indicated that
several of the differentially expressed proteins are strictly
related to glycolysis (P¼ 3 10 13) and gluconeogenesis
(P¼ 2 10 8) (Figure 2c). In particular, the increased
expression levels of key enzymes of fermentative glycolysis
such as pyruvate kinase M2 (PKM2) and lactate dehydro-
genase A (LDH-A) in spheres compared with SDACs might
indicate that spheres essentially metabolize glucose
through a non-oxidative pathway even under normoxic
conditions. This hypothesis is in line with the reported
upregulation of hypoxia-inducible factor 1a (HIF-1a) in
CSC12,21 and with the predicted activation of HIF-1a-
dependent pathway as suggested (z-score¼ 2.791) by the
higher expression in BCSC as compared with SDACs of
several proteins involved in this pathway such as triose-
phosphate isomerase 1, phosphoglycerate kinase 1, galectin 1,
LDH-A, heat-shock 70-kDa protein, glyceraldheyde 3-phos-
phate dehydrogenase, enolase 1, and aldolase A. Indeed,
Figure 1 Data quality evaluation, Venn analysis, and expression ratios for significantly regulated proteins in BCSCs compared with SDACs. Analytical reproducibility of
mass spectra was assessed in BCSCs, and cells were allowed to differentiate as SDACs for 3.5 and 7 days. Bar charts show the mass relative standard deviation (RSD) and
the intensity and retention time coefficients of variation (% CV) of exact mass retention time clusters detected in BCSCs (a, b, c), and SDACs collected at 3.5 days (d, e, f) and
7 days (g, h, i) post-differentiation (pd). (j) Four-way Venn diagram analysis of differentially expressed proteins identify 15 loci. Numbers in parentheses represent the total
number of identified proteins clustered in each locus. BCSCs compared to SDACs 3.5 days pd show 25 and 5 proteins specifically up-regulated and down-regulated,
respectively; BCSCs show 4 proteins up-regulated compared to SDACs 7 days pd; BCSCs show 19 and 5 proteins up-regulated and down-regulated, respectively compared
to SDACs regardless of differentiation time. The Swiss-Prot accession numbers are listed in table (see the Supplementary Tables S1 and S2 for a detailed description).
Analysis was performed using the four-way Venn Diagram Generator freely available at http://www.pangloss.com/seidel/Protocols/venn4.cgi. (k) Bar chart displays the mean
protein expression level ratios (n¼ 3) of 19 and 5 proteins up- and down-regulated, respectively in BCSCs compared to SDACs regardless of differentiation time . The red line
indicates the expression ratio¼ 1
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a western blotting (WB) analysis confirms that BCSCs
express higher levels of HIF-1a as compared with SDACs
(Figure 2d).
Targeted metabolomics shows increased lactic
fermentation rate and inhibition of fatty acid (FA)
beta-oxidation in BCSCs. In order to verify whether
BCSCs were more glycolytic when grown as spheroids than
when grown as SDACs, we performed targeted metabolomic
analysis of glycolysis intermediates. We found that levels of
fructose 1,6-diphospate, pyruvate, lactic acid, and ribose 5-
phosphate were significantly higher in BCSCs (Figure 3a,
Supplementary Table S5). In addition, we did not find
significant differences in concentrations of Krebs cycle
intermediates with exception of succinic acid, which was
significantly higher in BCSCs (Figure 3a, Supplementary
Table S5), and fumaric acid, which was higher in BCSCs, but
the difference with SDACs was not statistically significant
(mean±S.D.¼ 1995±257 and 1233±638ng/mg 1 in
BCSCs and differentiated cells, respectively; P¼ 0.204).
Our data also indicate relevant alterations of acylcarnitines
(AcCs) and amino acids (AA) profiles in BCSCs. The
concentrations of valine (Val), ornitine, phenylalanine,
arginine (Arg), tyrosine, serine, histidine (His), proline,
glycine (Gly), and lysine/glutamine increased in BCSCs as
compared with SDACs (Figure 3b; Supplementary Table
S5). Both Lys and Gln are undistinguishable by LC-MS/MS,
and we have been able to assess their overall concentration.
In contrast, alanine (Ala) significantly decreased in
BCSCs compared with SDACs (Figure 3b; Supplementary
Table S5).
Of note, we found a significant lower levels of free carnitine
in spheres as compared with SDACs (Figure 3b,
Supplementary Table S5), suggesting the inhibition of AcCs
synthesis and finally of FA beta-oxidation. Consistently with
this hypothesis, short, medium, and long-chain AcCs were
undetectable in BCSCs. In contrast, AcCs were all quantifi-
able in SDACs (Supplementary Table S5).
BCSCs show higher activity of key enzymes of
anaerobic glucose metabolism. We further validated the
expression level of PKM2 and LDH-A, key enzyme of aerobic
glycolysis, by WB analysis of protein extracts collected from
BCSCs and SDACs. We confirmed that PKM2 and LDH-A
were significantly upregulated in BCSCs compared with
SDACs (Figure 4a, P¼ 0.008 and 0.034, respectively; n¼ 3).
Furthermore, BCSCs displayed increased PK (mean±
S.D.¼ 2.5±0.7 and 1.0±0.2 mmol/mgProtein/min in BCSCs
and SDACs, respectively; P¼ 0.0001; n¼ 6) and LDH-A
(mean±S.D.¼ 2.0±0.8 and 1.3±0.1mmol/mgProtein/min in
Figure 2 Functional and protein network analysis indicates increased glycolytic activity and activation of HIF-1a pathway in BCSCs. Ingenuity Pathway Analysis of
differentially expressed proteins in BCSCs compared with SDACs result in two interaction network related to (a) the haematological, immunological, and inflammatory
diseases and (b) the free radical scavenging and cancer pathway. Diagrams show focus genes (the differentially expressed proteins) that are depicted in green
(downregulated) or red (upregulated). Solid and dashed lines indicate the direct and indirect interactions, respectively, and the arrows indicate the modulatory role of proteins
or endogenous chemicals. (c) The canonical pathways associated with BCSCs are glycolysis, gluconeogenesis, and superoxide radical degradation. Functional pathway
analysis was performed using the Ingenuity Pathway Analysis tool for the significantly regulated proteins in BCSCs compared with SDACs. The bar graph shows the scores
( log10P) associated to the pathways enriched with regulated proteins as determined using right-tailed Fisher’s exact test with thresholdo0.050. The yellow line indicates
the ratio calculated as the number of proteins in a given pathway that meet the cutoff criteria (P¼ 0.050) divided by the total number of molecules that make up that pathway.
(d) BCSCs upregulate normoxic HIF-1a. Nuclear extracts were assessed for HIF-1a and laminin b by WB. WB shows that the HIF-1a expression level significantly decreases
in cells allowed to differentiate as SDACs for 3.5 days
Increase of glycolytic activity in breast cancer stem cells
D Ciavardelli et al
4
Cell Death and Disease
54
BCSCs and SDACs, respectively; P¼ 0.044; n¼ 6) activity
(Figures 4b and c).
In order to confirm that the metabolic differences observed
are indeed due to differences between CSCs and more
differentiated cancer cells, we sorted CD24 /low cells within
the sphere culture, supposed to be the less differentiated
more stem-like cells, and compared them with a more
differentiated population expressing higher CD24 levels. We
assessed the expression levels and enzymatic activities of
LDHandPK in CD24 /low andCD24þ BCSCs. In accordance
with a more glicolitic phenotype, CD24 /low cells show higher
levels (Figure 4d) and activities of PK (mean±
S.D.¼ 19.2±0.3 and 2.0±0.4mmol/mgProtein/min in CD24 /low
and CD24þ cells, respectively; P¼ 6 10-13; n¼ 6) and LDH
(mean±S.D.¼ 3.6±0.3 and 2.5±0.5mmol/mgProtein/min in
CD24 /low and CD24þ cells, respectively; P¼ 0.002; n¼ 6)
(Figures 4e and f) as compared with CD24þ cells.
Glucose 6-phosphate dehydrogenase (G6PDH) is the key
enzyme of pentose phosphate pathway, the metabolic
process providing NADPH to the cells that is required for
anabolic pathways. Our proteomic data also show that
G6PDH is more expressed in BCSCs although the difference
with SDACs is not statistically significant (data not shown).
Indeed by WB analysis, we show that G6PDH is upregulated
in spheres compared with SDACs (P¼ 0.036; n¼ 3;
Figure 4a), and its activity is significantly increased
(mean±S.D.¼ 2.3±0.8 and 1.2±0.3mmol/mgProtein/min in
BCSCs and differentiated cells, respectively;P¼ 0.004; n¼ 6;
Figure 4g). According to the increase of G6PDH expression
and activity, we found a decreased NADPþ /NADPH ratio
in spheres (mean±S.D.¼ 0.94±0.05 and 1.063±0.004 in
BCSCs and SDACs, respectively; P¼ 0.013, Figure 4h).
These results suggest increased biosynthesis of NADPH
through the pentose phosphate pathway in BCSCs compared
with SDACs.
BCSCs show increased reduced nicotinamide adenine
dinucleotide (NADH) consumption and cytosolic ATP
production. Adenosine diphosphate (ADP)/ATP and
NADþ /NADH ratios are indices of aerobic or anaerobic energy
metabolism, cellular energy turnover, and redox cellular state.
We found that NADþ /NADH ratios are significantly higher in
BCSCs compared with SDACs (mean±S.D.¼ 11.9±0.6 and
6.7±0.3 in BCSCs and differentiated cells, respectively; P¼ 2
 10 4, Figure 4i). This is associated with the increase of
NADH consumption and decreased NADþ production in
BCSCs. In fact, NADH concentrations (mean±S.D.¼
0.06±0.04 and 0.13±0.02mmol/l in BCSCs and SDACs,
respectively; P¼ 0.050) as well as NADþ levels
(mean±S.D.¼ 0.73±0.04 and 0.88±0.07mmol/l in BCSCs
and SDACs, respectively; P¼ 0.045) significantly decrease in
BCSCs compared with SDACs.
BCSCs also show an increased ADP/ATP ratio
(mean±S.D.¼ 0.23±0.03 and 0.15±0.06 in BCSCs and
differentiated cells, respectively; P¼ 0.016, Figure 4j).
Of note, we found that treatment with rotenone, an
uncoupling agent of the electron transport chain (ETC),
increases the ADP/ATP ratio in SDACs (mean±
S.D.¼ 0.13±0.02 and 0.247±0.006 for control and SDACs
treated with rotenone, respectively; P¼ 0.001), while it has no
effect on the ATP production in BCSCs (mean±
S.D.¼ 0.21±0.02 and 0.20±0.01 for control and BCSCs
treated with rotenone, respectively; P¼ 0.732). These find-
ings suggest that uncoupling of ETC markedly inhibits ATP
Figure 3 Targeted metabolomics reveals significant alterations of glycolytic intermediates, glucose-derived non-essential amino acids, free carnitine, and AcCs,
suggesting increased lactic fermentation and inhibition of FAoxidation in BCSCs. Bar graphs show the mean concentrations of (a) glycolytic and Krebs cycle intermediates and
(b) amino acids and free carnitine in BCSCs and SDACs. Results of targeted metabolomic analysis are available in the Supplementary Table S5. The differences shown in the
bar graphs are all significant (two-tailed t-test, Po0.050). Concentrations are expressed as ng/mg (wet weight). Bars show the mean value±S.D. (n¼ 6)
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production in SDACs but not in BCSCs that rely on lactic
fermentation (Figure 4j).
2-deoxyglucose (2-DG) inhibits BCSCs’ growth and
survival. Overall, our data indicate that BCSCs display an
anaerobic metabolic phenotype compared with SDACs.
Therefore, we tested the effect, on BCSCs’ growth and
survival, of 2-DG, a compound known to inhibit the first phase
of glycolysis, alone or in combination with Doxo, a chemother-
apeutic agent used for the treatment of breast cancer.
Our results show that Doxo exerts a cytostatic effect on
BCSCs but a very modest, if any, toxic effect (Figures 5a and b).
Notably, BCSCswere substantially blocked in theG2 phase of
cell cycle (data not shown). In contrast, 2-DG provides a
significant time-dependent cytotoxic effect inducing up to 44%
apoptosis after 48 h of treatment (Figure 5b).
Interestingly, the combination of 2-DGwith Doxo results in a
higher cytotoxic effect compared with the treatment with Doxo
alone or 2-DGalone after 2 days reaching 80%apoptosis after
48 h (Figure 5b). As expected, more differentiated cells are
more responsive to Doxo; however they appear less sensitive
to 2-DG than BCSCs (Figure 5c). This is in line with a less
glycolityc metabolism. Again, the combined treatment results
in a much higher response also in SDACs (Figure 5c).
Discussion
Growing evidence show that a subset of cancer cells, known
as CSCs, are key drivers of tumour progression, being the
clonogenic population that supports tumour growth. Accord-
ing to the CSC model, failure to eradicate these cells with
current therapies can result in tumour recurrence. As these
Figure 4 The expression levels and activities of glycolytic enzymes are increased in BCSCs and correlate with altered energy and redox status of BCSCs. (a) WB showing
PKM2, LDH-A, and G6PDH expression in BCSCs compared with SDACs. b-Actin is used as a protein-loading control. A representative WB of three independent experiments
is shown. (b) PK and (c) LDH, and enzyme activities evaluated in spheres (BCSCs) as compared with differentiated cells (SDACs). Bar graphs show the mean activity (n¼ 6)
expressed as mmol/mgProtein/min, and bars represent the S.E.M. (d) WB showing the expression of PKM2 and LDH-A in cells sorted for CD24 expression. b-Actin is used as a
loading control. (e) PK and (f) LDH activity in CD24 /low cells compared with CD24þ BCSCs. Bar graphs show the mean activity (n¼ 6) expressed as mmol/mgProtein/min,
and bars represent the S.E.M. (g) G6PDH enzyme activity evaluated in spheres (BCSCs) as compared with differentiated cells (SDACs). Bar graphs show the mean activity
(n¼ 6) expressed as mmol/mgProtein/min, and bars represent the S.E.M. (h) NADPþ /NADPH, (i) NADþ /NADH, and (j) ADP/ATP ratios in BCSCs compared with SDACs.
Treatment with rotenone does not affect ATP production in BCSCs, whereas strongly increases the ADP/ATP ratio and inhibits mitochondrial ATP production in SDACs. No
changes in the ADP/ATP ratio are observed in BCSCs and SDACs after addition of dimethylsulphoxide (DMSO) alone used as a vehicle control. Bars show the mean
value±S.D. (n¼ 3). *Po0.050 (unpaired two-tailed t-test or two-factor ANOVA)
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cells are in general highly chemo- and radio-resistant, there is
an urgent need for therapeutic agents to selectively target this
population.2,3 Several signal transduction pathways have
been shown to contribute to the stem-like phenotype and have
been proposed as potential therapeutic targets; moreover,
recent studies indicate that targeting CSC metabolism in
combination with classical chemotherapeutic agents may
provide valuable strategy to eradicate CSCs. Our integrated
proteomic and targeted metabolomic analysis suggest that
BCSCs are more dependent on anaerobic glucose metabo-
lism than more differentiated tumour cells.
Increased glycolytic flux and lactate production even in the
presence of oxygen suggest a switch of BCSC metabolism
from oxidative phosphorylation to aerobic glycolysis, a
phenomenon well known as Warburg effect. Furthermore,
upregulation of aerobic glycolysis has been shown to correlate
with increased tumour aggressiveness and the development
of multi-drug resistance.22,23
Warburg effect has been considered a cellular response to
hypoxic conditions in the tumour microenvironment and the
adaptive overexpression of the transcription factor HIF-1a that
can promote the survival of cancer cells. The higher levels of
HIF-1a in spheres, predicted in silico and effectively observed
in BCSCs even upon normoxic conditions, results in the
increased expression levels of proteins involved in glucose
transport and metabolism as well as lactate production
through the induction of LDH-A, the key enzyme of glucose
fermentation.24 It has been shown that lactate and pyruvate,
found significantly increased in BCSCs, upregulate hypoxia-
inducible genes independently of hypoxia by stimulating the
accumulation of HIF-1a.25 Interestingly, we also found that
BCSCs are enriched in the Krebs cycle intermediate
succinate and show a trend toward increased fumarate
concentration. Succinate and fumarate promote HIF-1a
accumulation through the inhibition of the oxygen-dependent
prolyl hydroxylase domain enzymes that catalyze HIF-1a
degradation, thus providing supporting evidences for
increased HIF-1a in BCSCs upon normoxic conditions.
LDH-A is thought to be a major molecular mediator of the
Warburg effect. LDH-A and LDH-B genes encode for two
protein, namely M and H, respectively, that combine to give
five isoenzymes, which differ in electrophoretic mobility and
Michaelis–Menten constants for lactate and pyruvate. LDH-A,
overexpressed in BCSCs, is associated with the conversion of
pyruvate to lactate, suggesting increased lactic fermentation
in these cells. This hypothesis was supported by the increase
of LDHPyr-Lac activity and lactic acid found in spheres.
Increased local concentration of the toxic lactic acid and
decreased extracellular pH have been recently associated to
the Warburg effect and appear to be advantageous for
invasion and tumourigenesis.26–28
PKM2 is a low activity isoform of PK that promotes the
aerobic glycolysis and contributes to anabolic metabo-
lism.17,29 It is known that PKM2 replaces the normal PK
enzyme in proliferating and tumour cells,30 and a PKM1 (a
highly active PK isoform) to PKM2 isoform switch has been
associated with increased fermentative metabolism,
increased pyruvate and lactate production, and lower oxygen
consumption.17 Notably, PKM2 activity relies on allosteric
activation by fructose 1,6-diphosphate31 and serine.32 The
increased PK activity in the BCSCs is consistent with our data
showing a significant increase of these two allosteric effectors
in BCSCs as compared with SDACs. Furthermore, PK has a
global regulatory role in biosynthetic AA metabolism and
affects the concentration of free AAs.33 In particular, PKM2
upregulation has been shown to stimulate de novo serine
biosynthesis,34 which in turn can allosterically activate PKM2,
consistently with the higher serine levels that we found in
BCSCs. The upregulation of PKM2 and the increase of PK
activity may also correlate with the increase of Arg, Val, and
His that have been previously reported.33 The higher
biosynthesis rate of glucose-derived non-essential AAs linked
to the increase of PK activity suggests that BCSCs divert
glucose-derived carbon into non-ATP-producing pathways
supporting cellular biomass increase.
The increased expression levels and activity of G6PDH and
the increase of ribose 5-phosphate in BCSCs clearly indicates
the activation of the pentose phosphate pathway. These
findings support the idea that BCSCs shift from catabolic
metabolism aimed at energy production toward an anabolic
Figure 5 2-DG induces apoptosis of BCSCs, and its effect is increased by the combination with doxorubicin. (a) BCSCs are treated with doxorubicin (Doxo) and 2-deoxyglycose
(2-DG) alone or the combination of Doxo and 2-DG (Doxoþ 2-DG). Doxo treatment provides cytostatic effect, but cell counts does not significantly differ 24 and 48 h after Doxo
administration (Fischer’s LSD post-hoc test, P¼ 0.768). In contrast, treatment with 2-DG alone decreases BCSCs counts compared with control, 24 h (Fischer’s post-hoc test,
P¼ 0.055) and 48 h (P¼ 8 10 4) Doxo treatment. The treatment with Doxoþ 2-DG significantly decreases cell counts compared with 24 h (P¼ 0.0009) and 48 h
(P¼ 1 10 6) Doxo treatment and 48 h treatment with 2-DG alone (Fischer post-hoc test, P¼ 0.002). Evaluation of apoptosis in (b) BCSCs and (c) SDACs treated for 48 h with
2-DG, Doxo, or a combination of the two. The percentage of hypo-diploid events evaluated by Flow Cytometry after propidium iodide staining is shown
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state aimed at supplying biosynthesis precursors, such as
NADPH. According with this hypothesis, the NADP/NADPH
ratio is significantly decreased in spheres, indicating
increased intracellular NADPH levels.
BCSCs also show a high ADP/ATP ratio that may indicate
decreased production of oxidatively derived mitochondrial
ATP, and thus alternative ATP-generating pathways in
BCSCs as well as increased levels of cytosolic ADP, required
to maintain the high rate of glycolysis. Of note, the treatment
with rotenone, amitochondrial complex I inhibitor, significantly
impairs ATP production of cells upon differentiation without
significant effects on BCSCs. Therefore, BCSCs are less
dependent on the mitochondrial activity than normal cancer
cells and rely on aerobic glycolysis for ATP production.
It has been reported that glycolytic cells show low cytosolic
and mitochondrial NADþ /NADH ratios that inhibits the
tricarboxylic acids cycle (TCA) favouring anaerobic glycoly-
sis.35 Furthermore, enhancement of NADþ /NADH levels
inhibits tumourigenesis and metastasis in breast cancer.36
Unexpectedly, BCSCs are characterized by higher NADþ /
NADH level compared with SDACs. This seems to be in
contrast with the aggressive phenotype of this cells and their
tumour-forming ability. However, our data are consistent with
the hypothesis that BCSCs can consume NADH without
producing ATP from mitochondrial electron transport. The
decrease of NADH levels and the corresponding increase of
NADþ /NADH ratio in BCSCs could be related to the increase
of homolactic fermentation rate to regenerate a sufficient
NADþ pool and maintain the high rates of glycolysis,
increasing NADH consumption or to the inhibition of the
TCA cycle. In fact, it is known that increased concentration of
TCA cycle intermediates inhibits the cycle. The increase of
succinate concentration and the trend toward significant
increase of fumarate in BCSCs may partly explain the
increased NADþ /NADH ratio through the inhibition of the
TCA cycle. The strong inhibition of FA beta-oxidation that we
observed in BCSCs provides further evidences of silencing of
mitochondrial activity. Although the exact role of inhibition of
FA oxidative catabolism inhibition is currently unclear, these
preliminary results warrant further investigations.
It is worthy of note that the Warburg effect has been linked to
mitochondrial stability and the cellular redox balance in cancer
cells.37 Promoting glycolysis and limiting mitochondrial activity
may inhibit mitochondrial reactive oxygen species (ROS)
production. It has been recently demonstrated that low levels
of ROS generation through the glycolytic shift contributes to
maintaining a CSC phenotype.9 We found that BCSCs not only
rely on aerobic glycolysis but also strongly overexpress several
antioxidant enzymes such as mitochondrial superoxide dis-
mutase and synthesize more NADPH than differentiated cells.
Increased NADPH biosynthesis may indicate increased source
of reducing equivalents and an improvement of the anti-oxidant
defence through the proxiredoxin, thioredoxin, and glutathione
systems. Of note, it has been recently shown that the key
regulator of aerobic glycolysis PKM2 has a relevant role in
maintaining cellular redox homeostasis allowing greater diver-
sion of glycolytic intermediates into pentose phosphate pathway
and NADPH biosynthesis in response to oxidative stress.38
Therefore it is possible that BCSCs set in motion such
mechanisms to counteract ROS.
Pharmacological targeting of aerobic glycolysis overcomes
the drug resistance of CSCs isolated from several solid
tumours. In particular, it has been shown that inhibition of
glycolysis restores drug sensitivity in high malignant tumour
cells through the inactivation of ABC transporters that provide
the efflux mechanism for chemotherapeutic drugs in CSCs.39
The synthetic glucose analogue, 2-DG is one of the glycolysis
inhibitors that has been shown to inhibit solid tumour growth
and is currently under Phase I/II clinical trials.40,41 Of note, it
has been recently suggested that combination of 2-DG with
widely used chemotherapeutics such as trastuzumab may be
a valuable strategy to overcome drug-resistant BCSCs.42
Here we show that acute treatment with 2-DGhas a significant
cytotoxic effect and induces apoptosis of BCSCs. These
findings are consistent with data showing that 2-DG
significantly affects the ability of CSCs to form spheroids.14
The cytotoxic effect of 2-DG have been previously explained
not only by inhibition of glycolysis and the following metabolic
stress but also by indirect effects on several signalling
pathways such as inhibition of mammalian target of rapamycin
signalling43 or direct effects on pro-apoptotic proteins, such as
Bcl-2 homologous antagonist/killer.44
In contrast, the widely used chemotherapeutic drug Doxo
provides only a cytostatic effect on CSCs and has been shown
to lead to enrichment of cells with CSC characteristics within
the population, thus potentially increasing resistance and risk
of recurrence.45 Interestingly, we found that the combination
of Doxo with 2-DG shows a synergic effect, significantly
enhancing BCSCs’ death in a time-dependent manner.
Moreover, the combined treatment has an important effect
also on more differentiated cancer cells, suggesting that this
combination may target different cancer cell populations.
Doxo is known to increase ROS production, which can
mediate mitochondrial damage and apoptosis in a p53-
independent manner.46,47 It is also known that 2DG treatment
results in increased ROS.48,49 This may provide a rationale for
the enhancement of the effect of Doxo by 2-DG. On the other
hand, combining 2-DG with other drugs may enhance the low
in vivo cytotoxicity of 2-DG40 and overcome the cytostatic
effect of classical chemotherapeutic agents as well. In fact,
targeting aerobic glycolysis with 2-DG markedly overcomes
Doxo resistance of BCSCs, thus providing promising phar-
macological application against BCSCs.
Materials and Methods
Chemicals. All chemicals were supplied by Sigma-Aldrich (Shnelldorf,
Germany) and Fluka (Shnelldorf, Germany) unless otherwise stated.
Tissue collection, isolation, and culture of cancer cells. Human
breast cancer tissues were obtained from patients undergoing surgery in
accordance with the ethical standards of the institutional Committee on Human
Experimentation (authorization no. CE-ISS 09/282). Tumour tissues were
mechanically and enzymatically digested with collagenase (1.5 mg/ml; Gibco Life
Technologies, Grand Island, NY, USA) and hyaluronidase (20 mg/ml) in DMEM
(Gibco), shaking for 1 h at 37 1C. The resulting cell suspension was plated in
ultra-low attachment flasks (Corning Incorporated, Corning, NY, USA) in serum-
free medium supplemented with basic fibroblast growth factor (10 ng/ml) and
epidermal growth factor (20 ng/ml) as previously described.50 This procedure
yielded BCSC lines that were subjected to genotyping to validate each cell line’s
individuality and were further tested for their ability to generate tumour xenografts
that replicated the histology of the parental tumour. To achieve the in vitro
differentiation of BCSCs, dissociated sphere cells were cultured in DMEM for the
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indicated times (3.5 or 7 days) supplemented with 10% fetal bovine serum (FBS)
in adherent conditions. These cells were conventionally indicated as SDACs.18
Cell proliferation assay. Cell viability was determined at 24 and 48 h by
trypan blue dye exclusion assay following the treatment of BCSCs with 35 mmol/l
2-DG as previously reported,14 doxorubicin hydrochloride (1mmol/l), and a
combination of the two drugs at the same concentrations. Control samples were
performed in phosphate-buffered solution (PBS).
Cytofluorimetric analysis. Flow cytometric cellular DNA content evaluation
was performed according to Nicoletti et al.51 Briefly, cells were collected by
trypsinization, pelleted at 800 g for 10 min and fixed in 70% ethanol overnight at
 20 1C. Samples were then washed in PBS and incubated at 37 1C, for 15 min
with a 13 Kunitz units RNAse A solution and for 20 min with 50 mg/ml propidium
iodide. Twenty thousand events were acquired (FACSCanto II Instrument, BD
Biosciences, San Jose, CA, USA) and analysed by using the BD FACSDIVA
software (BD Biosciences).
Flow cytometric analysis of surface markers CD24 and cluster of differentiation
44 (CD44) was performed on 2 105 cells per sample. Cells were washed in PBS,
resuspended in 100ml of specific antibody (antibody-CD24-R-phycoerythrin-
cyanine dye7 (anti-CD24-PE-Cy7), 561646, BD Pharmingen (Franklin Lakes, NJ,
USA); antibody-CD44-allophycocyanin (anti-CD44-APC), 559942, BD Pharmingen)
diluted in 0.5% bovine serum albumin, and incubated for 20 min at room
temperature in the dark. Cell viability solution (555815, BD Biosciences) was used
for detection of non-viable cells according to manufacturer’s protocol. Samples were
then washed and stored at 4 1C in the dark until acquisition. A FACSCantoII flow
cytometer, running with FACSDiVa software (BD Biosciences), was used for sample
acquisition and analysis.
Cell sorting of CD44þ /CD24þ and CD44þ /CD24 /low sub-populations was
performed on single cell suspension from BCSC double stained with anti-CD24-PE-
Cy7 antibody and anti-CD44-APC antibody. Cells were sorted with fluorescence-
activated cell sorting Aria III cell sorter (BD Biosciences). Sub-populations of cells
co-expressing CD44 and CD24 at higher levels or CD24 weak/absent were
collected, and a small amount of cells were re-analysed to check for purity.
Immunoblotting. Cells grown as BCSCs and SDACs were collected by
centrifugation at 1200 revolutions/min. Cell pellets were washed twice with ice-cold
PBS, resuspended in a 50 mmol/l tris(hydroxymethyl)aminomethane (Tris)/HCl
(pH 7.5), 150 mmol/l NaCl, 1 mmol/l EDTA, 1 mmol/l NaF, 10% Glycerol (V/V),
1 mmol/l MgCl, 1% Triton X-100 (V/V) ice-cold buffer containing proteinase
inhibitor cocktail and incubated for 30 min on ice. Sample lysates were
centrifugated at 10 000 g for 10 min, and supernatants were collected. Equal
amounts of whole proteins extracts and nuclear extract (B-625 Sigma N-XTRACT,
Shnelldorf, Germany) for HIF-1a immunodetection were resolved on 10% sodium
dodecyl sulphate–polyacrylamide gel electrophoresis gel using a mini-gel
apparatus (GmbH Bio-Rad Laboratories, Hercules CA, USA), transferred onto
polyvinylidene fluoride membranes and subsequently blocked with 5% non-fat dry
milk in PBS/0.1% (V/V) Tween 20. Immunodetection was performed by incubating
the membranes with the different primary antibodies diluted in blocking buffer for
2 h at room temperature or overnight at 4 1C. The following antibodies were used:
anti-LDH (PA5-27406, Thermo Scientific, Rockford, IL, USA), anti-PKM2 (PA-
23034, Thermo Scientific), anti-G6PD (PA5-27359, Thermo Scientific), anti-HIF-1a
(NB100-449, Novus Biologicals, Cambridge, UK), anti-Actin (clone AC-15, A5441
Sigma-Aldrich), and anti-Laminin b (M-20) (sc-6217, Santa Cruz Biotechnology,
Inc., Santa Cruz, CA, USA). Immunoreactive bands were visualized with
SuperSignal West Dura Substrate (Pierce Biotechnology, Rockford, IL, USA).
Differential proteomic analysis. Sample preparation, data acquisition
and data processing were performed as previously described.52–54 A total of
100mg of protein extracts from the different conditions in separate experiments
were precipitated with a mix of ethanol, methanol, and acetone (ratio 2 : 1 : 1, V/V)
and then dissolved in 100 mmol/l Tris/HCl pH 7.9 containing 6 M urea and 0.1%
3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate and sonicated. The
reduction of proteins was performed by adding 100 mmol/l dithiothreitol (DTT) (1 h
at 36 1C) and 200 mmol/l iodoacetamide (1 h at room temperature). Protein
samples at a final concentration of 2mg/ml were digested with 1 : 20 (w/w)
sequence-grade trypsin (Promega, Madison, WI, USA) at 36 1C overnight. The
reactions were stopped by adding 1 ml of 10% (V/V) trifluoroacetic acid. A total of
0.25mg of the protein digestion was loaded onto the nanoACQUITY UPLC System
(Waters Corporation, Milford, MA, USA) coupled to a quadrupole-time of flight
(Q-Tof) Premier mass spectrometer (Waters Corporation). Before loading, a
digested enolase from Saccharomyces cerevisiae (Waters Corporation) was
added to the sample as internal standard at a final concentration of 200 fmol/l.
Samples were injected onto a Symmetry C18 5 mm, 180 mm 20 mm precolumn
(Waters Corporation) for preconcetration and desalting and were subsequently
separated using a NanoEase BEH C18 1.7mm, 75mm 25 cm nanoscale LC
column (Waters Corporation) maintained at 35 1C. Mobile phase A was water with
0.1% formic acid, and mobile phase B was 0.1% formic acid in acetonitrile.
Peptides were eluted by a gradient of 3–40% mobile phase B over 150 min at a
flow rate of 250 nl/min followed by a gradient of 40–90% mobile phase B over
5-min and a 15-min rinse with 90% mobile phase B. The Q-Tof Premier mass
spectrometer (Waters Corporation) was programmed to step between low (4 eV)
and high (15–40 eV) collision energies using a scan time of 1.5 s over 50–1990 m/
z. Samples from each condition were run at least in triplicate. The best replica for
each condition was used for the subsequent analysis. The Continuum LC-MS data
were processed and searched using ProteinLynx GlobalServer v2.3 (PLGS)
(Waters Corporation). Protein identification was performed using the embedded
ion accounting algorithm of the software and by searching a Uniprot/SWISSProt
human database release 2011_02 (20253 entries), to which the sequence from
the enolase of S. cerevisiae was appended. The parameters for the database
search were as follows: automatic tolerance for precursor ions, automatic
tolerance for product ions, minimum of three fragment ions matched per peptide,
minimum of seven fragment ions matched per protein, minimum of two peptides
matched per protein, one missed cleavage, and carbamidomethylation and
oxidation of methionine as modifications. The false positive rate of the
identification algorithm is typically 3–4% with a randomized database appended
to the original one, which is five times the size of the original utilized database.55,56
The identified proteins displayed in the protein table were normalized against the
P00924 entry (Enolase S. cerevisiae), and peptides from Enolase S. cerevisiae
digestion that were the most reproducible for retention time and intensity deriving
(m/z 807.42, m/z 814.49, m/z 1286.71, m/z 1288.70, m/z 1755.94, m/z 1789.83,
m/z 1840.89) were used to normalize the EMRT table, the list of paired peptide
exact masses and retention time. The list of normalized proteins was screened
according to the following criteria: proteins that were identified in at least two out of
the three injections of the same conditions; proteins with 0oPo0.05 or
0.95oPo1, and proteins with an expression level ratio between the conditions
41.3 on decimal scale. If 0oPo0.05, the likelihood of downregulation is
495%, and if 0.95oPo1 the likelihood of upregulation is 495%. Setting the
threshold of ratio at 1.3 on a decimal scale allowed us to consider the average
relative fold change ±0.30 on a natural log scale. This setting is typically 2–3
times higher than the estimated error of the intensity measurements.56
Targeted metabolomic analysis by GC–MS. GC–MS analysis of cell
lysates was performed as previously described.57 Briefly, cell samples
(approximately 1.5 106 cells) were extracted with a solution of ethanol/water
(50ml, 80 : 20, V:V), and cell homogenate (50 ml) were precipitated with 100ml of
cold 0.1% (V/V) methanolic trichloroacetic acid immediately after homogenization.
Internal standards (13C4 malic acid,
13C4 succinic acid,
13C6 glucose; IS) were then
added to give a final concentration of 10 mg/ml. Samples were centrifuged at
10 000 g for 30 min, and supernatants were collected and dried in a SpeedVac
system (ThermoSavant, Waltham, MA, USA). The dried extracts were derivatized
with 20 ml of 20 mg/ml of methoxyamine hydrochloride solution in pyridine for
60 min at 70 1C followed by reaction with 20ml of N,O-bis(trimethylsilyl)trifluor-
oacetamide with 1% of trimethylchlorosilane for 60 min at 70 1C. GC–MS analysis
was performed using a 6890N gas-chromatograph equipped with a 7863 Series
auto-sampler and coupled with a 5973N mass spectrometer (Agilent Technologies,
Palo Alto, CA, USA) operating in electron impact ionization mode. Three
microlitres were injected in pulsed-splitless mode by applying a pressure of 80 psi.
The injector temperature was kept at 250 1C. Chromatographic separations were
obtained using a fused silica capillary column HP-5MS (30 m x 0.25 mm, Agilent
Technologies). Helium was used as carrier gas at a constant flow rate of 1 ml/min.
The GC oven was programmed as follows: start at 70 1C (hold time 1 min), which
was raised at 4 1C/min to 300 1C (hold time 5 min). The mass spectrometer was
automatically calibrated using per-fluoro tributylamine as calibration standard. For
quantification, the mass spectrometer was used in the selective ion monitoring
mode, and mass spectra were recorded in positive modes by monitoring the
following ions: m/z 174 (pyruvic acid; IS: 13C3 pyruvic acid, m/z 177), m/z 147
(lactic acid; IS: 13C4 succinic acid, m/z 251), m/z 247 (succinic acid; IS:
13C4
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succinate, m/z 251), m/z 245 (fumaric acid; IS: 13C4 malic acid, m/z 236), m/z 233
(malic acid; IS: 13C4 malic acid, m/z 236); m/z 328 (glyceraldheyde 3-phosphate;
IS: 13C4 malic acid, m/z 236), m/z 357 (3-phosphoglyceric acid; IS:
13C4 malic acid,
m/z 236), m/z 375 (citric acid; IS: 13C4 malic acid, m/z 236), m/z 319 (glucose; IS:
13C6 glucose, m/z 323), m/z 387 (glucose 6-phosphate; IS:
13C6 glucose, m/z
323), and m/z 459 (fructose 1,6-diphosphate; IS: 13C6 fructose 1,6-diphosphate,
m/z 462). Mass spectrometer operating parameters were: interface temperature
300 1C, ion source 250 1C, and quadrupole 150 1C. The external standard method
and internal standard correction were applied for quantification of target
metabolites. Data acquisition was performed using the G1701CA ChemStation
software (Agilent Technologies).
Determination AAs and AcCs. AA and AcCs analysis was performed by
LC-MS/MS as previously described.58,59 Cell samples (approximately 1.5 106
cells) were extracted with a solution of Ethanol/Water (50ml, 80 : 20, V:V). The
samples were then sonicated and centrifuged (15 600 r.p.m. at 4 1C for 20 min),
and the supernatant was recovered. The lysate (7ml) were added to 100ml of the
stable isotope-labeled IS obtained from the NeoBase Non-derivatized MSMS Kit
(Perkin Elmer Life and Analytical Sciences, Turku, Finland). The sample were
analysed by direct infusion mass spectrometry using a LC-MS/MS system
consisting of an Alliance HT 2795 HPLC Separation Module coupled to a Quattro
Ultima Pt ESI tandem quadrupole mass spectrometer (Waters Corporation). The
instrument was operated in positive electrospray ionization mode using MassLynx
V4.0 Software (Waters Corporation). A detailed description of electrospray
ionization mass spectrometry acquisition parameters are available in
Supplementary Table S6. Auto data processing was performed using the
NeoLynx (Waters Corporation) software.
Pyruvate kinase activity. PK activity was measured by converting the
product pyruvate into lactate using LDH, with a concomitant conversion of NADH
to NADþ , resulting in a decrease in absorbance at 340 nm.60 In all, 7 106 cells
were lysed in 200ml of buffer containing 10 mmol/l Tris–HCl (pH 7.5), 1.5 mmol/l
MgCl2, 20 mmol/l NaCl, 1 mmol/l DTT, 1 mmol/l phenylmethylsulfonyl fluoride, and
protease inhibitor cocktail. After two centrifugations at 17 000 g for 30 min each,
PK activity was measured in the supernatant by a LDH-coupled assay. The 200-ml
reaction mixture was prepared on ice containing 100 mmol/l Tris–HCl (pH 8.0),
100 mmol/l KCl, 10 mmol/l MgCl2, 0.5 mmol/l EDTA, 0.2 mmol/l NADH, 1.5 mmol/l
ADP, 5 mm phosphoenolpyruvate, and 200 units/ml LDH. The reaction was
initiated by the addition of 0.7mg of total cell extract. PK activity was calculated at
37 1C by monitoring the absorbance at 340 nm every 30 s for 5 min in an
microplate reader (Spectra max 190, Molecular Devices, Sunnyvale, CA, USA).
A unit of PK activity is defined here as the amount of enzyme required to oxidize
1mmol of NADH per minute under these experimental conditions.
LDH activity. Direct LDH activity (LDHPyr-Lac) was spectrometrically assayed
as previously described61,62 using a tunable microplate reader (Spectra max 190,
Molecular Devices). Briefly, cell pellets were lysed in 0.010 mol/l PBS (20 ml/g of
pellet, wet weight; pH¼ 7.4). Cell lysates were centrifuged at 2000 g for 3 min
at 4 1C to remove cell debris. Supernatants were further centrifuged 8000 g for
10 min at 4 1C in order to obtain cytosolic fractions. Protein concentration was
determined according to the Bradford assay.63 Therefore, pyruvate (25ml, 2.50 g/l)
and NADH (100ml, 0.3 g/l) were added to the samples (10ml corresponding
to 0.5mg of total proteins) and the decrease of absorbance at 340 nm
was measured at 37 1C every 30 s for 5 min. LDHPyr-Lac activity is expressed
as mmol/mgprotein/min.
G6PDH activity. G6PDH was assayed using a tunable microplate reader
(Spectra max 190, Molecular Devices), according to the spectrophotometric
methods previously described64 with minor modifications. Cell pellets were
homogenized, and protein quantification were performed as described for LDH
activity assay. To measure G6PDH activity, the sample (10 ml corresponding to
0.5mg of total proteins) was added to a solution containing glucose 6-phosphate
(0.2 mmol/l), NADPþ (0.1 mmol/l), Tris/HCl buffer (50 mmol/l, pH¼ 8.1), and
MgCl2 (1 mmol/l). The final volume was 150ml. The increase of absorbance at
340 nm was measured every 30 s for 5 min at 37 1C. G6PDH activity was
expressed as mmol/mg protein/min.
NADþ /NADH and NADPþ /NADPH determination. NADþ /NADH
ratio were measured by a ultrasensitive colorimetric assay (EnzyChrom
NADþ /NADH Assay Kit (E2ND-100), BioAssay Systems, Hayword, CA, USA)
according to the manufacturer’s instructions. This assay is based on a LDH cycling
reaction.65 Briefly, cells were lysed with either 100ml NADþ extraction buffer for
NADþ determination or 100 ml NADH extraction buffer for NADH determination.
After heating at 60 1C for 5 min, 20ml of assay buffer and 100ml of the opposite
extraction buffers (NADH extraction buffer or NADþ extraction buffer,
respectively) were added. The samples were then centrifuged at 14 000 r.p.m.
for 5 min, and the supernatants (40ml) were used for NADþ /NADH assays. The
optical density (OD) was read at 565 nm in a tunable microplate reader (Spectra
max 190, Molecular Devices) for time 0 and after 15 min. NADþ and NADH
concentrations were measured as: (DOD-b0)/b1, where b0 and b1 are the
intercept and slope of the external calibration curve.
NADPþ /NADPH ratio were measured by a ultrasensitive colorimetric assay
(EnzyChrom NADPþ /NADPH Assay Kit (ECNP-100), BioAssay Sistems) following
the manufacturer’s instructions. This assay is based on a glucose dehydrogenase
cycling reaction.65 The absorbance was measured at 565 nm using a tunable
microplate reader (Spectra max 190, Molecular Devices), and the same procedure
applied for NADþ /NADH determination was performed. All analysis were
performed in triplicate.
ADP/ATP ratio determination. ADP/ATP ratio was measured based on
luciferin–luciferase reaction using Enzylight ADP/ATP ratio assay kit (ELDY-100)
(BioAssay Systems) following the manufacturer’s instructions. Briefly, BCSCs
cells were seeded in a 96-well flat-bottom plate and incubated for 3 days to allow
for cell differentiation and recovery (1 104 cells at 100 ml per well). BCSCs
(1 104 cells) were treated with the assay buffer (90 ml) containing luciferin–
luciferase. After 1 min, luminescence (relative light units (RLU) A) was recorded
by Lumat LB 9507 Ultra Sensitive Tube Luminometer (Berthold Technologies,
Oak Ridge, TN, USA). The luminescence was read also after 10 min (RLU B).
This measurement provided background before measuring ADP. Therefore, 5 ml
ADP reagent was added to each well, and after 1 min, luminescence (RLU C)
was obtained. ADP/ATP ratio was measured as: (RLU CRLU B)/RLU A. All
analysis were performed in triplicate. The same procedure was applied for the
measurement of ADP/ATP ratio in BCSCs and SDACs following treatment with
rotenone (50 mmol/l) for 60 min.
Statistical and bioinformatic analysis. Differences between the
protein expression levels, enzymatic activities, and metabolite concentrations
in BCSCs and SDACs were assessed by unpaired two-tailed t-test. Two-factor
ANOVA followed by Fisher’s least significant difference (LSD) post-hoc test was
performed in order to assess the significance of the treatment effects. Data
were ranked and aligned where Levene test failed to show homoscedasticity.
Aligned rank transformation (ART) of data was performed using the ART web
software available at http://faculty.washington.edu/aimgroup/proj/art/artweb/.66
Treatment (PBS, Doxo, 2-DG, and Doxoþ 2-DG) and the treatment time (24 or
48 h) were the independent factors. P-values o0.050 were considered
statistically significant. Statistical analysis was performed using the Statistica
6.0 (StatSoft Inc., Tulsa, OK), XLStat2007.1 (Microsoft, Redmond, WA, USA)
and Microsoft Excel software.
Protein network analysis was performed using the Ingenuity Pathway Analysis
(IPA) application (Ingenuity System, http://www.ingenuity.com). IPA constructs
hypothetical protein interaction clusters on the basis of the Ingenuity Pathways
Knowledge Base. Direct and indirect relationships between the identified proteins
were shown as networks on the base of all genes, and endogenous chemicals
present in the Ingenuity Knowledge Network scores are calculated as  log
(P-value) and indicate the likelihood that focus genes (i.e., the identified proteins
within a specific network) are clustered together. Biological functions and canonical
pathways over-represented among the identified proteins were also assigned to
networks stored in the Ingenuity Pathways Knowledge Base. Biological functions
and canonical pathways were ranked in accordance to their significance.
Significance was evaluated by exact Fisher’s test. A P-value of 0.01 corresponding
to a score of 2 was considered the cutoff for the analysis.
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